Apparatus and method for delivering a closure element

Information

  • Patent Grant
  • 8758398
  • Patent Number
    8,758,398
  • Date Filed
    Friday, September 7, 2007
    17 years ago
  • Date Issued
    Tuesday, June 24, 2014
    10 years ago
Abstract
An apparatus for delivering and deploying a closure element to an opening formed in a body lumen, including a delivery assembly positionable through the tissue and into the opening. The delivery assembly includes a distal locator portion and a carrier assembly oriented proximal to the distal locator portion. The distal locator portion is configured to selectably engage the body lumen adjacent to the opening, and the carrier assembly is configured to carry and support the closure element in a substantially tubular configuration. The carrier assembly is further configured to urge the closure element toward an expanded cross-sectional dimension for deployment thereof, such that the closure element is oriented to engage the tissue when deployed and, when released, to return to the natural, substantially planar configuration and the natural cross-section dimension wherein the engaged tissue is drawn substantially closed.
Description
BACKGROUND OF THE INVENTION

1. The Field of the Invention


The present invention relates generally to an apparatus and method for closing and/or sealing openings in a body lumen and/or tissue. More particularly, the present invention relates to an apparatus and method for delivering a closure element for closing a puncture in a blood vessel or other body lumen formed during a diagnostic or therapeutic procedure.


2. The Relevant Technology


Catheterization and interventional procedures, such as angioplasty or stenting, are generally performed by inserting a hollow needle through a skin and tissue and into a vascular system. A guide wire may be advanced through the needle and into the blood vessel accessed by the needle. The needle then is removed, enabling an introducer sheath to be advanced over the guide wire into the vessel, e.g., in conjunction with or subsequent to a dilator. A catheter or other device may then be advanced through a lumen of the introducer sheath and over the guide wire into a position for performing a medical procedure. Thus, the introducer sheath may facilitate introducing various devices into the vessel, while minimizing trauma to the vessel wall and/or minimizing blood loss during a procedure.


Upon completing the procedure, the devices and introducer sheath may be removed, leaving a puncture site in the vessel wall. External pressure may be applied to the puncture site until clotting and wound sealing occur. This procedure, however, may be time consuming and expensive, requiring as much as an hour of applied pressure. It is also uncomfortable for the patient, and requires that the patient remain immobilized in the operating room, catheter lab, or holding area. In addition, a risk of hematoma exists from bleeding before hemostasis occurs.


Various devices have been suggested for percutaneously sealing a vascular puncture by occluding the puncture site. For example, U.S. Pat. Nos. 5,192,302 and 5,222,974, issued to Kensey et al., describe the use of a biodegradable plug that may be delivered through an introducer sheath into a puncture site. Another technique has been suggested that involves percutaneously suturing the puncture site, such as that disclosed in U.S. Pat. No. 5,304,184, issued to Hathaway et al.


To facilitate positioning devices that are percutaneously inserted into a blood vessel, “bleed back” indicators have been suggested. For example, U.S. Pat. No. 5,676,974, issued to Kensey et al., discloses a bleed back lumen intended to facilitate positioning of a biodegradable plug within a puncture site. This device, however, requires that an anchor of the plug-be positioned within the vessel, and therefore, may increase the risk of over-advancement of the plug itself into the vessel.


Alternatively, U.S. Pat. No. 5,674,231 issued to Green et al., discloses a deployable loop that may be advanced through a sheath into a vessel. The loop is intended to resiliently expand to engage the inner wall of the vessel, thereby facilitating holding the sheath in a desired location with respect to the vessel.


Accordingly, while these closure devices and procedures are met with varying degrees of success, there is always a need for a new and improved apparatus and technique for delivering a closure element to a vascular puncture site or other opening through tissue.


BRIEF SUMMARY OF THE INVENTION

The present invention is directed toward an apparatus and method for delivering a closure element through tissue and into an opening formed in, or adjacent to, a wall of a blood vessel or other body lumen of any size.


In one embodiment, the present invention includes an apparatus for positioning a closure element to close an opening in a body lumen. Such an apparatus includes a carrier assembly and a distal tissue engaging device. The carrier assembly is configured to support a closure element in a substantially tubular configuration in a first diameter. The closure element is configured to substantially uniformly deform from a substantially tubular configuration to a natural, substantially planar configuration. The distal tissue engaging device is selectably axially displaceable relative to at least a portion of the carrier assembly. As such, the distal tissue engaging device moves between a tissue engaging condition and a tissue closing condition. The tissue engaging condition engages opposing portions of an arterial wall defining said body lumen adjacent to the opening. The tissue closing condition urges the engaged opposing portions of the arterial wall substantially together such that the closure element may be deployed from the delivery assembly to engage the opposed portions of the arterial wall and to return to the natural, substantially planar configuration.


In one embodiment, the distal tissue engaging device includes two or more opposed engaging tongs having respective end tips configured to open radially in directions extending beyond the first diameter to initially engage the opposing portions of the arterial wall, in the engaging condition.


In one embodiment, the carrier assembly further includes a cover member protecting at least the closure element which is contained therein.


In one embodiment, the distal tissue engaging device is integral with a distal end of the cover member.


In one embodiment, the carrier assembly is formed and dimensioned for sliding axial, reciprocating, receipt in a lumen of an introducer sheath extending through said tissue and terminating proximate the opening. The tissue engaging device is configured to cooperate with the introducer sheath to enable movement between the engaging condition and the closing condition.


In one embodiment, the present invention includes an apparatus for delivering and deploying a substantially resilient closure element through tissue to an opening in a body lumen perimeterically defined by opposing arterial walls. The closure element is configured to substantially uniformly deform from a natural, substantially resilient planar configuration to a substantially tubular configuration having a substantially natural transverse cross-sectional dimension. The apparatus includes a delivery assembly positionable through the tissue toward the opening in the body lumen. Also, the delivery assembly has a distal tissue engaging device and a carrier assembly configured to support the closure element in the substantially tubular configuration in a first diameter. The distal tissue engaging device is selectably axially displaceable relative to at least a portion of the carrier assembly between a tissue engaging condition and a tissue closing condition. The tissue engaging condition engages the opposing arterial walls of the body lumen adjacent to the opening. The tissue closing condition urges the engaged opposing arterial walls substantially transversely together such that the closure element may be deployed from the delivery assembly, while substantially maintained in the first diameter, into the opposing arterial walls. The closure element is oriented to engage the engaged opposing arterial walls when deployed and to return to the natural, substantially planar configuration and the natural, transverse cross-sectional dimension such that the engaged opposing arterial walls are drawn substantially closed.


In one embodiment, the apparatus includes a locator configured to position the carrier assembly and distal tissue engaging device adjacent to the opening in the body lumen. Also, the locator has a distal locator portion selectably controllable between an unexpanded state and an expanded state for engaging the opposing portions of the arterial wall of the body lumen.


In one embodiment, the apparatus includes a distal tissue locator portion contained on the delivery assembly. The distal tissue locator portion is configured to facilitate detection of the body lumen and includes one or more expansion elements configured to expand substantially transversely with respect to a longitudinal axis of the distal locator portion.


In one embodiment, the distal locator portion is selectably controllable between an unexpanded state and an expanded state for engaging said opposing arterial walls of said body lumen.


In one embodiment, while in the unexpanded state, the distal locator portion has a transverse cross-sectional dimension less than that of the opening. Also, while in the expanded state, the distal locator portion has a transverse cross-sectional dimension greater than or substantially equal to that of said opening.


In one embodiment, the present invention includes an apparatus for positioning a closure element to close an opening in a body lumen. Such an apparatus includes a carrier assembly and a distal tissue engaging device. The carrier assembly has a tubular body configured to receive a closure element in a substantially tubular configuration in a first diameter prior to deployment. Also, the tubular body has a distal port. The distal tissue engaging device is disposed within the tubular body and is selectably axially displaceable from the distal port. A portion of the distal tissue engaging device is biased to selectively radially extend outwardly from a longitudinal axis of the tubular body to intravascularly engage opposing arterial walls of the body lumen. A portion of the distal tissue engaging device urges the engaged opposing portions of the arterial wall substantially together as the distal tissue engaging device moves proximally. The closure element is then deployed to engage the opposed portions of the arterial wall.


In one embodiment, the carrier assembly includes a cover member defining a lumen configured for slidable receipt of the closure element therein.


In one embodiment, the carrier assembly includes a pusher member that slides for distally deploying the closure element.


In one embodiment, the pusher member and the tubular body are disposed as a nested, telescoping tube set with a common longitudinal axis.


In one embodiment, the tubular body includes a tissue locator portion. The tissue locator portion includes a bleed back shaft having a bleed back port distally disposed on a distal end of the tubular body.


In one embodiment, the present invention includes a closure system for closing an opening formed in a body lumen perimeterically defined by opposing arterial walls. Such a closure system includes a closure element, a delivery assembly, and a pusher member. The closure element is adapted to deform from a natural, substantially resilient planar configuration to a substantially tubular configuration that has a substantially natural transverse cross-sectional dimension. The delivery assembly is capable of being positioned through the tissue and into the opening in the body lumen.


Additionally, the delivery assembly has an elongated body, a carrier assembly and a distal tissue engaging device. The carrier assembly includes a carrier seat configured to carry and peripherally support the closure element in the substantially tubular configuration in a first diameter. The distal tissue engaging device is selectably, axially displaceable relative to the carrier seat between an engaging condition and a closing condition. The engaging condition engages the opposing arterial walls of the body lumen adjacent to the opening. The closing condition urges the engaged opposing arterial walls substantially transversely together such that the closure element may be deployed from the carrier assembly, while substantially maintained in the first diameter, into the opposing arterial walls.


The pusher member is slidably disposed about the elongated body for relative axial sliding displacement therebetween. The pusher member has a contact portion disposed proximally adjacent to the closure element in order to selectively distally deploy the closure element from the carrier assembly. The closure element is deployed in the substantially tubular configuration so as to engage the opposing arterial walls and to return to the natural, substantially planar configuration and the natural, transverse cross-sectional dimension such that the engaged opposing arterial walls are drawn substantially closed.


In one embodiment, the delivery assembly includes a tubular body supporting the carrier seat. Also, the tubular body defines a central receiving lumen extending longitudinally therethrough that is configured for sliding support of the tissue engaging device for axial movement between the engaging condition and the closing condition.


In one embodiment, the pusher member comprises one or more distally extending longitudinal extensions.


In one embodiment, the closure system includes a locator slidably receivable within the pusher member and the delivery assembly.


In one embodiment, the present invention includes a method for closing an opening defined by edges of arterial walls of a body lumen. Such a method includes the following: positioning a distal end region of a carrier assembly through tissue adjacent to an opening so that a distal tissue engaging device engages opposing portions of arterial walls, the distal end region of the carrier assembly includes a carrier seat configured to seat said closure element thereon in a substantially tubular configuration, having a first diameter; urging the engaged arterial walls radially inwardly and toward one another such that at least opposed edges of the arterial walls drawn with the first diameter of the closure element; and distally deploying the closure element from the carrier assembly without further substantial radial expansion for the closure element, in the substantially tubular configuration, such that the closure element engages the arterial walls, and returns to the natural, planar configuration and the natural cross-section wherein the tissue is drawn substantially closed.


In one embodiment, the engagement of the arterial walls is performed by extravascularly engaging the arterial walls with the tissue engaging device.


In one embodiment, the engagement of the arterial walls is performed by intravascularly engaging the arterial walls with the tissue engaging device.


In one embodiment, the method includes placing a distal end region of a locator portion through tissue into the opening.


In one embodiment, the method includes engaging the arterial walls adjacent to the opening.


In one embodiment, the method includes orientating the carrier assembly proximal to the locator portion.


These and other embodiments and features of the present invention will become more fully apparent from the following description and appended claims, or may be learned by the practice of the invention as set forth hereinafter.





BRIEF DESCRIPTION OF THE DRAWINGS

To further clarify the above and other advantages and features of the present invention, a more particular description of the invention will be rendered by reference to specific embodiments thereof which are illustrated in the appended drawings. It is appreciated that these drawings depict only typical embodiments of the invention and are therefore not to be considered limiting of its scope. The invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:



FIG. 1 provides a general illustration of an apparatus for closing openings formed in blood vessel walls constructed in accordance with the present invention.



FIG. 2 illustrates one embodiment of a delivery assembly for the apparatus of FIG. 1.



FIG. 3A illustrates a top view of one embodiment of a closure element in a natural, planar configuration and with a natural cross-section for use with the apparatus of FIG. 1, prior to curing.



FIG. 3B illustrates a side view of the closure element of FIG. 3A.



FIG. 3C illustrates a top view of the closure element of FIGS. 3A-3B after a natural cross-section of the closure element has been reduced, via a curing process.



FIG. 3D illustrates a side view of the closure element of FIG. 3C.



FIG. 3E illustrates a side view of the closure element of FIGS. 3C-3D as the closure element transitions from the natural, planar configuration to a tubular configuration.



FIG. 3F illustrates a top view of the closure element of FIGS. 3C-3D upon completing the transition from the natural, planar configuration to a substantially tubular configuration, albeit a natural tubular configuration.



FIG. 3G illustrates a side view of the closure element of FIG. 3F.



FIG. 4A illustrates one embodiment of a distal locator portion and a carrier seat of a carrier assembly of FIG. 2, both of which are illustrated in an unexpanded state.



FIG. 4B illustrates the distal locator portion and a carrier seat of FIG. 4A, both of which are illustrated in an expanded state.



FIG. 4C illustrates one embodiment of a proximal end region of the delivery assembly of FIG. 2.



FIG. 5A illustrates one embodiment of a carrier assembly for the apparatus of FIG. 1.



FIG. 5B illustrates one embodiment of a pusher member for the carrier assembly of FIG. 5A.



FIG. 5C illustrates one embodiment of a cover member for the carrier assembly of FIG. 5A.



FIG. 6 illustrates a tube set and the delivery assembly of the apparatus of FIG. 1 mounted to a handle portion for operative manipulation thereof.



FIG. 7A illustrates the closure element of FIGS. 3A-3G prior to being disposed upon the carrier assembly of FIG. 5A.



FIG. 7B illustrates the closure element of FIGS. 3A-3G upon being disposed upon the carrier assembly of FIG. 5A, and further as the cover member of FIG. 5C receives the carrier assembly.



FIG. 7C illustrates the closure element of FIGS. 3A-3G being retained substantially within the carrier assembly of FIG. 5A when the carrier assembly is disposed substantially within the cover member of FIG. 5C.



FIG. 8A illustrates a sheath that is positioned through tissue and into an opening formed in a wall of a blood vessel, in one embodiment of the present invention.



FIG. 8B illustrates the locator portion and the carrier assembly of the delivery assembly of the apparatus being advanced distally into the blood vessel.



FIG. 8C illustrates a distal end region of the locator portion of FIG. 8B extending into the blood vessel and being transitioned into an expanded state.



FIG. 8D illustrates the distal end region of the locator portion of FIG. 8C being retracted proximally to engage an inner surface of the blood vessel wall, and the retraction of the sheath to expose the tissue engaging device, in a tissue engaging condition.



FIG. 8E illustrates engagement of the tissue engaging device of the apparatus of FIG. 8D with the blood vessel wall.



FIG. 8F illustrates movement of the tissue engaging device from the tissue engaging condition to a closing condition.



FIG. 8G illustrates the closure element being deployed and engaging tissue adjacent to the opening in the blood vessel wall.



FIG. 8H illustrates the closure element of FIG. 8G transitioning from the substantially tubular configuration to the natural, planar configuration while engaging the engaged tissue.



FIG. 9 is a side elevation view, in cross-section, of another embodiment of the clip applier apparatus having a tissue engaging device deployed from a central lumen of the tubular body, in a tissue engaging condition.



FIG. 10 is a side elevation view, in cross-section, of the clip applier apparatus of FIG. 9, illustrating the tissue engaging device in a closing condition.



FIG. 11 is a side elevation view, in cross-section, of the clip applier apparatus of FIG. 9, illustrating deployment of the closure element.



FIG. 12 is a side elevation view, in cross-section, of yet another embodiment of the clip applier apparatus also having a tissue engaging device deployed from a central lumen of the a tubular body, in a tissue engaging condition.



FIG. 13 is a side elevation view, in cross-section, of the clip applier apparatus of FIG. 12, illustrating the tissue engaging device in a closing condition.



FIG. 14 is a side elevation view, in cross-section, of the clip applier apparatus of FIG. 12, illustrating deployment of the closure element.



FIG. 15 is a side elevation view, in cross-section, of another embodiment of the clip applier apparatus also having a tissue engaging device deployed from a central lumen of a tubular body, in a tissue closing condition.





DETAILED DESCRIPTION

While the present invention will be described with reference to a few specific embodiments, the description is illustrative of the invention and is not to be construed as limiting the invention. Various modifications to the present invention can be made to the preferred embodiments by those skilled in the art without departing from the true spirit and scope of the invention as defined by the appended claims. It will be noted here that for a better understanding, like components are designated by like reference numerals throughout the various figures.


The apparatus is configured to receive and retain the closure element such that the closure element is disposed substantially within the apparatus. Thereby, if the apparatus is introduced via an introducer sheath, for example, the closure element can be disposed within, and delivered by way of, a lumen of the introducer sheath. The apparatus also is configured to engage the blood vessel wall adjacent to the opening and to position the closure element substantially adjacent to an outer surface of the blood vessel wall adjacent to the opening.


When properly positioned, the apparatus can be activated to distally deploy the closure element. During deployment, the apparatus preferably is configured to substantially uniformly expand the closure element beyond a natural cross-section of the closure element such that the closure element, when deployed, is configured to engage significant amount of the blood vessel wall and/or tissue. Engaging the blood vessel wall and/or tissue, the closure element is further configured to return to the natural cross-section. Thereby, the engaged blood vessel wall and/or tissue are drawn substantially closed and/or sealed, such that, for example, hemostasis within the opening is enhanced.


In one specific embodiment, an apparatus is provided for delivering and deploying a substantially resilient closure element through tissue to an opening in a body lumen perimeterically defined by opposing arterial walls. The closure element is configured to substantially uniformly deform from a natural, substantially resilient planar configuration to a substantially tubular configuration, having a substantially natural transverse cross-sectional dimension. The apparatus include a delivery assembly positionable through the tissue and into the opening in the body lumen, and having a distal tissue engaging device and a carrier assembly. The carrier assembly is configured to carry and support the closure element in the substantially tubular configuration in a first diameter. The distal tissue engaging device is selectably axially displaceable relative to at least a portion of the carrier assembly between a tissue engaging condition and a tissue closing condition. In the tissue engaging condition, the opposing arterial walls of the body lumen are engaged adjacent to the opening. In contrast, in the tissue closing condition, the engaged opposing arterial walls are urged substantially transversely together such that the closure element may be deployed from the delivery assembly, while substantially maintained in the first diameter, into the opposing arterial walls. The closure element is oriented to engage the engaged opposing arterial walls when deployed and to return to the natural, substantially planar configuration and the natural, transverse cross-sectional dimension such that the engaged opposing arterial walls are drawn substantially closed.


The distal tissue engaging device includes two or more opposed engaging tongs having respective end tips configured to open radially in directions extending beyond the first diameter of the carrier assembly to initially engage the opposing arterial walls, in the engaging condition. These engaging tongs are configured to close radially inward such that the engaged opposing arterial walls are disposed within the first diameter of the closure element, in the substantially tubular configuration, in the closing condition.


In another specific embodiment, the carrier assembly includes a cover member protecting the delivery assembly such that at least the closure element is contained therein. The cover member defines a lumen configured for slidable receipt of the closure element therein. The distal tissue engaging device is integral with a distal end of the cover member to enable movement of the two or more opposing tongs between the engaging condition and the closing condition.


Still another specific arrangement provides a delivery assembly that is formed and dimensioned for sliding axial, reciprocating, receipt in a lumen of an introducer sheath extending through the tissue and terminating proximate the opening. The tissue engaging device is configured to cooperate with the introducer sheath to enable movement between the engaging condition and the closing condition. Further, the two or more tongs are formed and dimensioned for sliding contact with the sheath lumen to effect movement between the engaging condition and the closing condition.


In yet another specific embodiment, the carrier assembly includes a carrier seat configured to seat the closure element, in the substantially tubular configuration, on the delivery assembly prior to deployment. The delivery assembly includes a tubular body supporting the carrier seat, and defines a central receiving lumen extending longitudinally therethrough that is configured for sliding support of the tissue engaging device for axial movement between the engaging condition and the closing condition. Each of the two or more tongs are bowed and biased radially outward, relative one another, from a longitudinal axis of the tubular body such that an end tip of each respective tong is urged outward and toward gripping intravascular engagement with an undersurface of the opposing arterial walls, in the engaging condition, when the tissue engaging device extends distally from the central lumen of the tubular body.


In another aspect of the present invention, a closure system is provided for closing an opening formed in a body lumen perimeterically defined by opposing arterial walls. The system includes a closure element adapted to deform from a natural, substantially resilient planar configuration to a substantially tubular configuration, having a substantially natural transverse cross-sectional dimension. A delivery assembly is positionable through the tissue and into the opening in the body lumen. The delivery assembly includes an elongated body, a carrier assembly and a distal tissue engaging device. The carrier assembly includes a carrier seat configured to carry and peripherally support the closure element in the substantially tubular configuration, in a first diameter. The distal tissue engaging device is selectably axially displaceable relative to the carrier seat between the engaging condition and the closing condition, while substantially maintaining the engaged walls within the first diameter. A pusher member is slidably disposed about the elongated body for relative axial sliding displacement therebetween. The pusher member includes a contact portion disposed proximally adjacent the closure element. The pusher member is applied to selectively distally deploy the closure element from the carrier assembly, in the substantially tubular configuration, to engage the opposing arterial walls and to return to the natural, substantially planar configuration and the natural, transverse cross-sectional dimension such that the engaged opposing arterial walls are drawn substantially closed.


In yet another aspect of the present invention, a method for closing an opening perimetrically defined by edges of the arterial walls of a body lumen is provided including placing a distal end region of a locator portion of a through tissue into the opening; and engaging the arterial walls adjacent to the opening. The method further includes positioning a distal end region of a carrier assembly through the tissue adjacent to the opening. The carrier assembly is oriented proximal to the locator portion, and the distal end region of the carrier assembly includes a carrier seat configured to seat the closure element thereon in a substantially tubular configuration, having a first diameter. The method includes urging the engaged arterial walls radially inward and toward one another such that at least opposed edges of the arterial walls drawn with the first diameter of the closure element. The closure element is distally deployed from the carrier assembly without further substantial radial expansion for the closure element, in the substantially tubular configuration, such that the closure element engages the arterial walls, and returns to the natural, planar configuration and the natural cross-section wherein the tissue is drawn substantially closed.


In one specific embodiment, the engaging of the arterial walls is performed by extravascularly engaging the arterial walls with a tissue engaging device. In contrast, the engaging of the arterial walls is performed by intravascularly engaging the arterial walls with a tissue engaging device.


Referring now generally to FIGS. 1-4 and 8A-8H, a clip or closure applier apparatus, generally designated 100, is provided for delivering and deploying a closure element 500 to an opening 610 formed in a body lumen, such as a blood vessel 600; the opening 610 of which is perimeterically defined by opposing tissue arterial walls 620′, 620″ (FIG. 8A). Briefly, as shown in FIGS. 3A-3G, the closure element 500 itself is configured to resiliently deform between a natural, substantially planar configuration (after a curing process (FIG. 3C)) to a substantially tubular configuration (FIGS. 3F and 3G). Further, the closure element can also be resiliently deformed and radially displaced up to an expanded substantially tubular configuration, having a greater cross-sectional dimension, from its natural substantially tubular configuration (FIGS. 8F and 8G), or can be displaced down to a reduced substantially tubular configuration, having a lesser cross-sectional dimension.


Returning to the clip applier apparatus 100, in accordance with the present invention, a delivery assembly, generally designated 200, is included that is positionable through the tissue 630 and into the opening 610. The delivery assembly 200 includes a distal tissue engaging device 400 and a carrier assembly 300, oriented just proximal to the distal tissue engaging device, that houses and supports the closure element 500″. The carrier assembly 300 includes a carrier seat portion 302 configured to carry and support the closure element 500″ in a slightly expanded substantially tubular configuration (FIG. 7A-7C), in a first diameter, that is slightly greater than that in a natural, substantially tubular condition.


The distal tissue engaging device 400 is selectably axially displaceable relative to the carrier assembly 300 between a tissue engaging condition (FIG. 8D) and a tissue closing condition (FIG. 8F). In the tissue engaging condition, the tissue engaging device 400 engages the opposing arterial walls 620′, 620″ (e.g., FIG. 8D-8E) of the body vessel 600 adjacent to the opening 610 so that the engaged walls can be pulled or urged radially inward or transversely toward one another in the closing condition (FIG. 8F-8G). Hence, in the closing condition, the engaging device 400 urges the opposing arterial walls 620′, 620″ at the opening 610, substantially closer together and toward one another radially. By closing the opposing arterial walls within the first diameter of the closure element 500″ (mounted about the carrier seat 302 in the substantially tubular configuration), the closure element can be deployed directly there from without having to further radially expand the same to sufficiently engage the tissue.


Hence, applying a pusher member 320 (as will be described), the closure element 500″, which is retained in the substantially tubular configuration, can be deployed into the opposing arterial walls (FIG. 8G). Subsequently, once the closure element engages the opposing arterial walls 620′, 620″ and is released from the delivery assembly, it returns to the natural, substantially planar configuration and the natural cross-section dimension such that the engaged opposing arterial walls are drawn substantially closed (FIG. 8H).


In accordance with the present invention, since the closure element 500″ can be deployed from the closure applier apparatus 100 without requiring substantial further radial expansion from the substantially tubular configuration atop the carrier assembly, the overall complexity of the closure applier can be significantly reduced. In turn, the diametric footprint can be significantly reduced, as compared to previous designs, which in effect permit the use of a smaller diameter GF introducer sheath. Moreover, a closure applier apparatus is provided that fully encloses the closure element within itself during advancement to the tissue site, prior to deployment and delivery to the targeted vessel walls. Unlike many current designs, the present invention significantly reduces potential tissue snag or contact by the closure element during advancement and positioning. This enclosure approach is similar to those disclosed in co-pending U.S. patent application Ser. No. 11/455,993, filed Jun. 19, 2006, and entitled “APPARATUS AND METHOD FOR DELIVERING A CLOSURE ELEMENT”; and U.S. patent application Ser. No. 10/356,214, filed Jan. 30, 2003, entitled “CLIP APPLIER AND METHODS OF USE” (hereinafter referred to as the '214 patent application), each of which is herein incorporated by reference in their entirely. These designs prove much more desirable and provide a basis for a wide range of medical applications, such as diagnostic and/or therapeutic procedures involving blood vessels or other body lumens of any size.


As will be discussed in more detail below, the clip applier apparatus 100 can deliver a closure element 500″ (shown in FIGS. 3F-G) through tissue 630 (shown in FIG. 8A) and into an opening 610 formed in and/or adjacent to and perimeterically defined perimetrically by the arterial walls 620 (e.g., the opposed arterial walls 620′, 620″) of a blood vessel 600 or other body lumen. The closure element (or clip) 500 preferably has a generally annular-shape body 510 (shown in FIGS. 3A-3B) defining a channel 540 and one or more barbs and/or tines 520 for receiving and engaging the blood vessel wall 620 and/or the tissue 630 around the opening 610. Although the closure element 500, when originally fabricated, has a natural shape and size, the closure element 500 can be deformed into other shapes and sizes, as desired, and is configured to return to the natural shape and size when released. For example, the closure element 500 can have a natural, planar configuration with opposing tines 520 and a natural cross-section 530 as shown in FIGS. 3A-3B. Via a heat-treating process, disclosed in U.S. Pat. No. 6,623,510 to Carley et al., incorporated herein by reference in its entirety, the natural cross-section 530 of the closure element 500 will be reduced to form a reduced closure element 500′ that has a natural, planar configuration with opposing tines 520 and a reduced cross-section 530′ as shown in FIGS. 3C-3D. By rotating the opposing tines 520 axially as shown in FIG. 3E, the cured closure element 500′ can be further deformed to form a substantially tubular closure element 500″ (shown in FIG. 3F) having a generally annular-shape body 510′ with an outer diameter 530′ and an inner diameter 550. In this substantially tubular configuration with the tines 520 in an axial configuration (FIG. 3G which is the configuration when loaded on the carrier assembly configuration, albeit slightly expanded), the resulting cross-section 530′ when loaded is expanded as well.


Being configured to draw the opposed blood vessel arterial walls 620′, 620″ and/or the tissue 630 adjacent to the opening 610 substantially closed and/or to enhance hemostasis within the opening 610, the closure element 500 can be formed from any suitable material, including any biodegradable material, any shape memory alloy, such as alloys of nickel-titanium, or any combination thereof As desired, the closure element 500 can include radiopaque markers (not shown) or can be wholly or partially formed from a radiopaque material to facilitate observation of the closure element 500 using fluoroscopy or other imaging systems. Exemplary embodiments of a closure element are disclosed in U.S. Pat. No. 6,197,042, in co-pending application Ser. Nos. 09/546,998; 09/610,238 and 10/081,726. The disclosures of these references and any others cited therein are expressly incorporated herein by reference.


With the exception of the last specific embodiment shown in FIG. 15, the clip applier apparatus 100 is configured to receive, retain and substantially enclose the closure element 500″ within the apparatus 100. In the embodiments of FIGS. 1-2 and 4-15, as will be described in greater detail below, the delivery assembly 200 includes an elongated tubular body 210 that supports a distal tissue locator portion 202 and the carrier seat 302 of the carrier assembly 300 that is disposed proximal to the locator portion. The carrier assembly 300 further includes a cylindrical cover member or garage tube 330 enclosing the pusher member 320, the tubular body 210 and the carrier seat 302 in a nested manner within its receiving lumen 334 until the closure element is prepared for deployment.


In each embodiment, if the apparatus 100 is introduced via an introducer sheath 640 (shown in FIG. 8A), for example, the closure element 500″ can be disposed entirely within the garage tube 330, and delivered by way of the lumen 644 (shown in FIG. 8A) of the introducer sheath 640. Being disposed substantially within the garage tube 330 of the clip applier apparatus 100 just prior to deployment of the closure element 500″, the delivery assembly 200 can deeply penetrate the tissue 630 adjacent to the opening 610 without inadvertently contacting or snaring it. The delivery assembly 200 can thus position the closure element 500″ substantially adjacent to an outer surface 620a (shown in FIG. 8A) of the blood vessel wall 620 adjacent to the opening 610.


Referring to the specific embodiments of FIGS. 1-2 and 4-15, each clip applier apparatus 100 includes a central distal tissue locator portion 202 and a carrier assembly 300 supported on the end of, and integrated with, the tubular body 210 of the delivery assembly 200. Briefly, the distal locator portion 202 is configured to facilitate location of the opening 610 into the blood vessel 600, relative to the carrier assembly 300 and the tissue engaging device 400 (e.g., FIGS. 8D and 8E).


The carrier assembly 300, on the other hand, is configured to carry and support the closure element 500″ in the substantially tubular configuration (FIGS. 3F and 3G), albeit in a slightly expanded configuration from its natural tubular configuration. In this manner, the resiliency of the closure element 500″ itself, together with the confinement of the cover member 330, function to secure it to the carrier seat 302 of the carrier assembly 300. When deployed, the closure element 500″ (in the substantially tubular configuration) is oriented with its tines directed distally to engage the blood vessel wall 620 and/or the tissue 630 around the opening 610, and to return to the natural, substantially planar configuration and the natural cross-section such that the engaged tissue is drawn substantially closed (FIG. 8H).


Once strategically oriented, the clip applier apparatus 100 can be activated to distally deploy the closure element 500″. It will be appreciated that although the closure element 500″ is capable of significantly greater radial expansion from its tubular configuration mounted to the carrier assembly 300 of the tubular body 210, the delivery assembly is designed to deploy the closure element 500″ directly from the carrier seat 302 without requiring any further significant radial expansion.


The apparatus 100 can be provided as one or more integrated components and/or discrete components. As shown in the embodiment of FIGS. 1-2 and 4-8, for example, the apparatus 100 can include an elongated delivery assembly 200 having an integral tissue engaging device 400, central vessel locator (or obturator) portion 202 and carrier assembly 300, that carries the closure element 500″ thereon, on a single subsystem. In contrast, in the embodiments of FIGS. 9-15, the tissue engaging device 400 is contained on a separate subsystem from the carrier assembly 300 and the vessel locator portion 202, all of which cooperate with one another to deploy the closure element.


In fact, in accordance with the present invention, it is the position, implementation and execution of the tissue engaging device 400 that differentiates each embodiment. In one specific embodiment, for example, the tissue engaging device 400 is disposed on the distal end to the cover member 330 (FIGS. 1-2, and 4-8), where it is selectively operated between the tissue engaging condition (FIGS. 8D, 8E) and the closing condition (FIGS. 8F, 8G). In contrast, in the embodiments of FIGS. 9-15, the tissue engaging device 400 is disposed within a central lumen 204 of the tissue locator portion 202, and is selectively operated as it is distally advanced from the lumen. It will be appreciated that these differing implementations of the tissue engaging devices will each be detailed separately below.


In each implementations, however, the tissue engaging device 400 is capable of gripping, snaring and/or piercing the tissue arterial walls 620, and urging them together and radially inward, toward one another, such that portions of the arterial walls 620′, 620″ are axially contained within the first diameter of the closure element 500″, in the substantially tubular configuration. As mentioned, this arrangement enables the deployment of the closure element 500″ directly from the carrier seat 302 of the carrier assembly 300 without requiring further radial expansion.


Referring back to FIGS. 4-8, the first specific embodiment will be described in detail. In this particular arrangement, the distal tissue locator portion 202 (obturator) is configured to extend into the opening 610 and selectably engage an inner surface 620b of the blood vessel wall 620 (FIG. 8D). Thereby, the distal locator portion 202 is configured to draw the blood vessel wall 620 taut, and maintain the proper position of the clip applier apparatus 100 as the blood vessel 600 pulsates. Briefly, in cooperation with the tissue engaging device 400 oriented at the distal end of the cover member 330, once the distal locator portion 202 is properly aligned and positioned, the tissue engaging device can be operated to engage the arterial walls, drawing them radially together as will be described below.


First, the delivery assembly 200 of this embodiment will be detailed which includes the tubular body 210, the carrier assembly 300 and the distal locator portion 202 integrated on a single subsystem. The tubular body 210 is preferably provided by a flexible, semi-rigid or rigid, tubular structure, such as an elongate rail, with a longitudinal axis 216. As illustrated in FIGS. 2 and 4A, the tubular body 210 has a proximal end region 210a and a distal end region 210b that supports the carrier seat 302 of the carrier assembly 300 just proximal to the distal locator portion 202.


The tubular body 210 is preferably of a predetermined length 218a and a predetermined outer cross-section 218b (FIG. 2), both of which can be of any suitable dimension. The distal section of the distal locator portion 202 preferably includes a substantially rounded, soft, and/or flexible distal end or tip 220 to facilitate atraumatic advancement and/or retraction of the distal section into the blood vessel 600. As desired, a pigtail (not shown) may be provided on the distal end 220 to further aid atraumatic advancement of the delivery assembly 200.


Turning now to FIGS. 4A and 4B, it will be appreciated that the distal locator portion 202 functions in a manner similar to those disclosed in co-pending application Ser. Nos. 09/732,835 and 10/081,723, the disclosure of which is expressly incorporated herein by reference. That is, the distal locator portion 202 is selectably controllable between an unexpanded state (FIG. 4A) and an expanded state (FIG. 4B). In the unexpanded state, the distal locator portion 202 has an unexpanded size; whereas, in the expanded state, it has an expanded size, which is greater than the unexpanded size in the unexpanded state. The distal locator portion 202 is configured to expand from the unexpanded size to the expanded size and/or to contract from the expanded size to the unexpanded size, and the expansion and contraction of the distal locator portion 202 preferably is substantially uniform about the longitudinal axis 216. For example, one or more expansion elements 230 can be provided on the distal locator portion 202 and can be configured to expand substantially transversely with respect to a longitudinal axis 216 of the locator portion 202. Preferably being substantially equally distributed about an outer periphery 212 of the distal locator portion 202, the expansion elements 230 may include radiopaque markers (not shown) or may be wholly or partially formed from a radiopaque material to facilitate observation of the expansion elements 230 and/or the distal locator portion 202 using fluoroscopy or other imaging systems.


At least one, and preferably all, of the expansion elements 230 of the distal locator portion 202 can comprise a substantially flexible member 230′ with a substantially fixed end region 230a′, an intermediate region 230b′, and a movable end region 230c′ as shown in FIGS. 4A-4B. For each substantially flexible member 230′, the proximal fixed end region 230a′ is fixedly coupled, relatively, with an intermediary support region 211 separating the distal locator portion 202 from the carrier assembly 300. In contrast, the movable end region 230c′ is movably coupled, relatively, with the intermediary support region 211, and configured to be axially movable relative to the fixed end region 230a′. When each movable end region 230c′ is axially moved toward the relevant fixed end region 230a′, the intermediate regions 230b′ buckle and/or expand transversely outwardly, thereby transitioning the distal locator portion 202 of the delivery assembly 200 from the unexpanded state to the expanded state. In contrast, the distal locator portion 202 transitions from the expanded state to the unexpanded state as each of the movable end regions 230c′ are axially moved away from the relevant fixed end region 230a′.


Hence, the expansion elements 230 are relatively resilient, and can buckle without plastic deformation or pure elastic deformation. Further, although the expansion elements 230 are shown as comprising the flexible members 230′ in FIGS. 4A-4B for purposes of illustration, it is understood that the expansion elements 230 can comprise any type of expansion elements and are not limited to the illustrated embodiments. For example, inflatable bladder type devices or the like may be employed to cause expansion of the expansion elements, such as a balloon, an expandable mesh or a slit hypotube, etc. In a preferred embodiment, the flexible members are constructed of nitinol.


Referring back to FIGS. 1 and 4-6, the delivery assembly 200 also includes the carrier assembly 300 positioned along the distal end of the tubular body 210, and oriented adjacent and proximate to the distal locator portion 202. The carrier assembly 300 is configured to receive and retain the closure element 500″ in the slightly expanded, substantially tubular configuration (shown in FIG. 7B), which preferably is disposed substantially within the cover member 330 of the carrier assembly 300. The carrier assembly 300 includes a substantially cylindrical-shaped carrier seat 302 configured to seat the closure element 500″ thereagainst. By parking the closure element 500″ within the garage tube 330 (or cover member) during vessel advancement or positioning, not only is any tissue snaring caused by the closure element reduced, but the closure element itself is protected within the confines of the cover member.


Turning now to FIGS. 5A-5C, the carrier assembly 300 preferably includes the carrier seat 302, the pusher member 320, and the cover member (garage tube) 330. These components are preferably provided as a plurality of nested, telescoping members with a common longitudinal axis 350. As mentioned, the substantially cylindrical-shaped seat surface or the carrier seat 302 is sized and dimensioned to have transverse cross-sectional dimension slightly greater than that of the closure element 500″, when the closure element is deformed to its natural substantially tubular configuration. Thus, the closure element 500 preferably is deformed from its natural, planar configuration (FIGS. 3A, 3B) to the natural, substantially tubular closure element 500″ (shown in FIGS. 3F, 3G). When being placed or positioned about an outer periphery of the carrier seat 302, the closure element must further be slightly radially expanded to fit thereover. In this arrangement, the tines 520 of the substantially tubular closure element 500″ are pointed substantially distally and ready for tissue engagement. Once seated, the closure element 500″ will primarily be retained in place using its own resiliency toward the natural planar position from the slightly expanded, substantially tubular configuration about the seat surface.


A biocompatible glue or adhesive may further be applied to facilitate retaining the closure element 500″ on the carrier seat 302 of the carrier assembly 300. Together with the internal restrictive or confining nature of the cover member 330, the glue or adhesive must be sufficient to overcome the resilient tendency of the closure element 500″ (FIG. 3G) to return to its natural planar condition (FIGS. 3A and 3B). By way of example, such glues and embedded adhesives include polymer coatings, Loctite, etc. It will further be appreciated that other techniques can be applied to retain the closure element 500″ to the carrier seat 302.


In accordance with the present invention, the pusher member 320 is configured to slidably receive at least a portion of the carrier seat 302, as well as the tubular body 210, with a receiving lumen 324 therein and an external surface 322b. The pusher member 320 is of a predetermined length 328a and a predetermined cross-section 328b, both of which can be of any suitable dimension. The predetermined length 328a of the pusher member 320 can be greater than or substantially equal to the collective predetermined length 218a and diameter 218b of the tubular body 210 and the carrier assembly 300. The predetermined length 328a of the pusher member 320, however, is preferably less than the collective predetermined length 218a of the tubular body 210 and the carrier seat 302, such that a distal end region 320b of the pusher member 320 is axially offset proximally from the distal end region 302b of the carrier seat 302. This axial offset, together with the cover member 330, defines an annular space 360 designated for receipt of the substantially tubular closure element 500″ about the carrier seat 302.


Being formed from a substantially rigid, semi-rigid, or flexible material, the pusher member 320 preferably is substantially tubular and defines receiving lumen 324 that extends substantially between the proximal end region 320a and the distal end region 320b. This lumen 324 is configured to slidably receive at least a portion of the tubular body 210 and the carrier seat 302 therethrough. The cross-section 328b of the pusher member 320 preferably is substantially uniform, and the distal end region 320b of the pusher member 320 can comprise one or more longitudinal extensions 325, which extend distally from the pusher member 320 and along the periphery of the carrier seat 302, as shown in FIG. 5B. The longitudinal extensions 325 preferably are biased such that the longitudinal extensions 325 extend generally in parallel with common longitudinal axis 350. The longitudinal extensions 325 are sufficiently flexible to expand radially, and yet sufficiently rigid to inhibit buckling.


As best shown in FIGS. 5A and 5C, the cover member 330 is configured to retain the substantially tubular closure element 500″ and the carrier assembly 300 substantially within a lumen 334 thereof prior to deployment. Being coupled with, and slidable relative to, the carrier seat 302 and the pusher member 320, the cover member 330 has a proximal end region 330a and a distal end region 330b and includes a predetermined length 338a and a predetermined cross-section 338b. Preferably being formed as a substantially rigid, semi-rigid, or flexible tubular member formed from a polymer, the cover member 330 has an outer periphery 332b and an inner periphery 332a that defines lumen 334. The lumen 334 extends substantially between the proximal and distal end regions 330a, 330b of the cover member 330 and can be configured to slidably receive at least a portion of the pusher member 320. When the cover member 330 is properly positioned over the pusher member 320 and the carrier seat 302, the distal end region 330b is configured to extend over the space 360, thereby defining an annular cavity for receiving and retaining the closure element 500″ in the substantially tubular configuration.


In one preferred embodiment, as best illustrated in FIGS. 5A, 5C, 7B and 7C, one or more longitudinal extensions 335 extend distally from the garage tube or cover member 330. Although the longitudinal extensions 335 can extend generally in parallel with common longitudinal axis 350, the longitudinal extensions 335 preferably are biased such that the plurality of longitudinal extensions 335 extend substantially radially inwardly as illustrated in FIGS. 5A and 5C. Thereby, the longitudinal extensions 335 can at least partially close the annular space 360 slotted for seating of the closure element 500″.


The cross-section 338b of the cover member 330 preferably is substantially uniform. In the embodiment of FIGS. 1, 2 and 4-8, the distal end region 330b of the cover member 330 is integrated with the tissue engaging device 400, as will soon be detailed. To permit the substantially tubular closure element 500″ to be deployed from the annular space 360, the cover member 330 can be slidably retracted, relative the carrier seat 302 to expose the mounted closure element 500″.


If the carrier assembly 300 is assembled as a plurality of nested, telescoping members as shown in FIG. 5A, the tubular body 210 of the delivery assembly is at least partially disposed within, and slidable relative to, the lumen 324 of the pusher member 320. The pusher member 320, in turn, is at least partially disposed within, and slidable relative to, the lumen 334 of the cover member 330. Hence, the longitudinal axis 216 of the locator portion 202, the carrier assembly 300 and the tubular body 210 (i.e., of the delivery assembly 200) are preferably substantially in axial alignment with the common longitudinal axis 350 of the pusher member 320 and the cover member 330.


In accordance with this embodiment of the present invention, the tissue engaging device 400 is disposed and oriented on the distal end of the cover member 330 for operation between the tissue engaging condition (FIGS. 8D, 8E) and the tissue closing condition (FIGS. 8F, 8G). As previously indicated, in the tissue engaging condition, the tissue engaging device 400 engages the opposing arterial walls 620′, 620″ (e.g., FIG. 8E) of the vessel 600 adjacent to the opening 610 so that they can be pulled or urged radially inward or transversely toward one another in the closing condition (FIG. 8F). In the closing condition, hence, the engaging device 400 urges the opposing arterial walls 620′, 620″ at the vessel opening 610, substantially radially together about axis 216 and toward one another. By closing the opposing arterial walls within the first diameter of the closure element 500″, the closure element can be deployed directly from the carrier seat 302 of the carrier assembly 300 without having to further radially expand to sufficiently engage the tissue.


As best illustrated in FIG. 7B, the engaging device 400 includes at least two opposing tongs 402, each of which extends distally from the distal end of the cover member and terminates at a tissue engaging tip 404. The tips 404 may be conventionally pointed shaped that facilitate penetration and/or snaring of tissue during operation. These tongs, preferably integral with the cover member or garage tube 330, are sufficiently flexible to enable control and operation in and by the GF sheath 640, yet are sufficiently rigid to enable extravascular penetration, snaring and/or grasping of the target arterial wall. In one specific configuration, for example, the distal end of the garage tube may be fabricated from a material having shape memory properties where, in use, the combined subsystem would cooperate the GF sheath 640 to operate and control the use of the tissue engaging device 400.


The two or more tongs 402 of the tissue engaging device 400 are configured and oriented for sliding reciprocal cooperation with an interior wall 642 of the sheath 640 to control movement and operation of the engaging device between the tissue engaging condition (FIGS. 8D, 8E) and the closing condition (FIGS. 8F, 8G). More specifically, the distal tips 404 of each tong 402, in the tissue engaging condition, will be manipulated to snare and/or engage the arterial walls 620′, 620″ being held taut by the tissue locator portion 202, in the expanded condition. Preferably, the engaging device distal tips 404 will be radially expanded or oriented at least as wide as the first diameter, relative to longitudinal axes 216, 350, of the closure element seated about the carrier seat 302. More preferably, the distal tips 404 will be radially expanded to a disposition greater than and beyond the first diameter to ensure sufficient snaring and/or engaging of the arterial walls surrounding the vessel opening 610. Accordingly, the tongs of the tissue engaging device are biased and/or have a disposition extending radially outward. Hence, by retracting the restrictive sheath 640 proximally relative to the garage tube 330 (or advancing the delivery assembly distally past the distal end of the sheath), the respective tongs 402 of the tissue engaging device 400 will be released and permitted to radially expand to the tissue engaging position (FIG. 8D).


Briefly, as will be described in greater detail below, once the arterial walls 620′, 620″ are snared or pierced by the tissue engaging device 400, in the tissue engaging condition, the GF sheath can be displaced distally, relative to the garage tube. Sliding contact between the interior wall 642 of the sheath and the outer facing surfaces 406 of the tongs 402 causes the distal tips of the engaging device to draw the tissue radially inward toward one another (FIG. 8F). As the interior wall 642 of the sheath is advanced distally, the increasing contact along the outer surfaces 406 of the tongs causes the distal tips to invert inwardly within the first diameter of the closure element in the substantially tubular configuration about the carrier seat 302, in the closing condition.



FIG. 6 best illustrates that the clip applier apparatus 100 includes a housing/handle 380 at a proximal end thereof suitable for gripping and manual support, manipulation and operation of the device and components thereof Preferably, the housing 380 is an elongated member having a proximal end 380a and a distal end 380b with a longitudinal axis 386. When the apparatus 100 is properly assembled, the tube set 305 of the delivery assembly 200 is at least partially disposed within the housing handle such that the pusher member 320 and the cover member 330 are slidable relative to the housing 380, the tubular body 210, the carrier seat 302 and the distal locator portion 202 thereof Further, respective distal end regions 210b, 320b and 330b extend from the distal end region 380b of the housing 380 such that the common longitudinal axis 350 (shown in FIG. 5A) of the tube set 305 is substantially axially aligned with the longitudinal axis 386 of the housing 380. Being configured to slidably retain the respective proximal end regions 210a, 320a and 330a, the housing 380 supports the tube set 305 and can have one or more handles 390 to facilitate use of the apparatus 100. The handles 390 extend substantially radially from the outer periphery 382 of the housing 380 and can be provided in the manner known in the art.


The present invention incorporates various switching systems, triggering systems, locking systems, etc. contained in the handle portion to effect use and operation of the delivery components described herein. While all these subsystems are not shown and described herein in detail, it will be appreciated that they are similar to the design and operation of the analogous subsystems shown and described in our '214 patent application, which as mentioned is incorporated by reference herein for all purposes.


By way of example, however, the locator portion 202 also can include a locator control system 240 that is coupled with the proximal end region 210a of the delivery assembly 200 and that is configured to selectively control the distal locator portion 202 between the unexpanded and expanded states (FIG. 4C). The locator control system 240 can selectively control the distal locator portion 202 between the unexpanded and expanded states, such as by being activated by a switching system (not shown). For example, a control member 250, such as a rod, wire, or other elongate member, can be moveably disposed within a lumen (not shown) formed by the tubular body 210 and extending substantially between the proximal end region 210a of the tubular body 210 and the distal locator portion 202. The control member 250 has a proximal end region 250a that is coupled with the locator control system 240, preferably through a control block (not shown, but operationally similar to the control systems and structures), and a distal end section (not shown) of the control member 250 that is coupled with the expansion elements 230, and/or the movable end regions 230c′ of the substantially flexible members 230′. The locator control system 240 can selectively transition the expansion elements 230, and/or the substantially flexible members 230′ of the distal locator portion 202 between the unexpanded and expanded states by moving the control member 250 axially relative to the tubular body 210.


The locator control system 240 preferably includes a locator release system (not shown, but one embodiment which may be similar to that disclosed in the '214 patent application) for maintaining the unexpanded state and/or the expanded state of the distal end region 210b, the expansion elements 230, and/or the substantially flexible members 230′. The locator release system is preferably configured to maintain the locator portion in the expanded state. Any type of locking system can be employed, and can be engaged, for instance, by activating the switching system. For example, once the substantially flexible members 230′ have entered the expanded state, the locator release system can secure the control member 250 to prevent axial movement relative to the tubular body 210, thereby maintaining the substantially flexible members 230′ in the expanded state.


The locator control system 240 also can be configured to disengage the locator release system, such that the distal end region 210b, the expansion elements 230, and/or the substantially flexible members 230′ can transition between the unexpanded and expanded states. The locator release system can be disengaged, for example, by activating an emergency release system (not shown). As desired, the locator control system 240 can further include a biasing system (not shown), such as one or more springs, to bias the distal end region 210b, the expansion elements 230, and/or the substantially flexible members 230′ to enter and/or maintain the unexpanded state when the locator release system is disengaged.


In use, the closure element 500″ is carried on the carrier seat 302, in the slightly radially expanded tubular configuration, and is disposed within the cover member 330. As shown in FIGS. 7A-7C, for example, the closure element 500′ can be slidably received over the distal locator portion 202 and the distal end region of the carrier assembly 300. The closure element 500″ is then seated and disposed about the periphery of the carrier seat 302 adjacent to the space 360, in the slightly expanded, substantially tubular configuration.


After being received over the distal end region 302b, the substantially tubular closure element 500″ is disposed in the space 360, and the tines 520 are directed substantially distally as shown in FIG. 7B. To improve the engagement between the closure element 500″ (shown in FIGS. 3A-3B) and the blood vessel wall 620 and/or tissue 630 (collectively shown in FIG. 8A), the substantially tubular closure element 500″ preferably is disposed on the carrier seat 302 such that the tines 520 are contained in a plane.


Once disposed in the space 360, the resiliency of the slightly expanded closure element 500″ and/or the addition of an adhesive or glue will facilitate retention of the element in place about the carrier seat. Moreover, the sliding receipt of the substantially tubular closure element 500″ and the distal end region 320b of the pusher member 320 within the lumen 334 of the cover member 330, as illustrated in FIGS. 7B and 7C, also cooperate to retain the closure element 500″ against the carrier seat 302. When the cover member 330 is properly positioned over the carrier assembly 300, the distal end region 330b (opposite of the proximal end region 330a) of the cover member 330 extends over the space 360 and defines the annular cavity for retaining the substantially tubular closure element 500″. As such, the closure element 500″ is disposed substantially between the outer periphery of the carrier seat 302 and the inner periphery 332a of the cover member 330 such that the substantially tubular closure element 500″ maintains the substantially tubular configuration with the tines 520 being directed substantially distally. As desired, the tube set 305 may slightly radially compress the substantially tubular closure element 500″ to facilitate seating against the carrier seat. The body 510 of the substantially tubular closure element 500″ can be disposed distally of the distal end region 320b of the pusher member 320, as illustrated in FIG. 7C, or can engage the distal end region 320b, as desired.


Turning now to FIGS. 8A-8H, operation of this specific embodiment will now be detailed. Initially, introducer sheath 640 may be inserted or otherwise positioned through skin 650 and tissue 630 and within the blood vessel 600 or other body lumen via the opening 610. Comprising a substantially flexible or semi-rigid tubular member, the sheath 640 has a proximal end region 640a and a distal end region 640b and includes a predetermined length and a predetermined cross-section, both of which can be of any suitable dimension. The sheath 640 also forms a peripheral surface 645 and a lumen 644 that extends along a longitudinal axis of the sheath 640 and substantially between the proximal and distal end regions 640a, 640b. The lumen 644 can have any suitable internal cross-section 648b and is suitable for receiving one or more devices (not shown), such as a catheter, a guide wire, or the like. The lumen 644 is configured to slidably receive tube set 305 and the delivery assembly 200 of the apparatus 100, including the nested tubular body 210, the carrier seat 302, the distal locator portion 202, pusher member 320 and the cover member 330 as a single unit. Accordingly, one significant advantage of the present invention is that, due to the reduced complexity of the cooperating componentry, the overall diametric footprint can be significantly smaller relative to the current systems. Hence, the entire nested tube set 305 may be slidably received in the lumen 644 of the introducer sheath 640 without requiring a radial expansion or splitting of the sheath 640. Such a configuration is beneficial in that, when required, the delivery assembly 200 can be retracted and reinserted unlike the previous designs that irreversibly radially expanded, stretched, split or severed the analogous sheaths.


The introducer sheath 640 may be advanced over a guide wire or other rail (not shown) that was previously positioned through the opening 610 and into the blood vessel 600 using conventional procedures. In one specific use, the blood vessel 600 is a peripheral blood vessel, such as a femoral or carotid artery, although other body lumens may be accessed using the sheath 640 as will be appreciated by those skilled in the art. The opening 610, and consequently the sheath 640, may be oriented with respect to the blood vessel 600 such as to facilitate the introduction of devices through the lumen 644 of the sheath 640 and into the blood vessel 600 with minimal risk of damage to the blood vessel 600. One or more devices (not shown), such as a catheter, a guide wire, or the like, may be inserted through the sheath 640 and advanced to a predetermined location within the patient's body. For example, the devices may be used to perform a therapeutic or diagnostic procedure, such as angioplasty, atherectomy, stent implantation, and the like, within the patent's vasculature.


After the procedure is completed, the devices are removed from the sheath 640, and the apparatus 100 is prepared to be slidably received by the lumen 644 of the sheath 640 as shown in FIG. 8B. Being in the unexpanded state, the distal end region of the distal locator portion 202, via tubular body 210, is slidably received by the lumen 644 and atraumatically advanced distally into the blood vessel 600 (FIG. 8B). Briefly, it will be appreciated that, due to the fixed configuration between the distal end region of the carrier assembly 300 and the proximal end region of the distal locator portion 202, in a support configuration, that the carrier seat 302, the pusher member 320 and the cover member 330, together with the closure element in the slightly expanded, substantially tubular configuration, are also advanced distally near the blood vessel 600 as a unit. Moreover, since the pusher member 320 and the cover member 330 are also coupled to the tubular body 210, those components are likewise advanced distally together with the locator portion 202. Once the distal end region of the distal locator portion 202 extends into the blood vessel 600, the distal locator portion 202 can transition from the unexpanded state (FIG. 8B) to the expanded state (FIG. 8C) by activating the switching system of the locator portion 202.


Turning now to FIG. 8D, the apparatus 100 and the sheath 640 then are retracted proximally until the distal end region of the locator portion 202 is substantially adjacent to an inner surface 620b of the blood vessel wall 620. The distal end region of the locator portion 202 thereby draws the opposing blood vessel walls 620′, 620″ taut and maintains the proper position of the apparatus 100 as the blood vessel 600 pulsates. Since the expanded cross-section of the expansion elements 230 is collectively greater than or substantially equal to the cross-section of the opening 610 and/or the cross-section of the lumen 644, the expansion elements remain in the blood vessel 600 and engage the inner surface 620b of the blood vessel wall 620. The expansion elements 230 can frictionally engage the inner surface 620b of the blood vessel wall 620, thereby securing the apparatus 100 to the blood vessel 600. The sheath 640 is then retracted proximally such that the distal end region 640b of the sheath 640 is substantially withdrawn from the blood vessel 600, as shown in FIG. 8D, permitting the apparatus 100 to access the blood vessel wall 620.


While the relative distance between the distal end region of the carrier assembly 300 (i.e., the carrier seat 302) and the proximal end region of the distal locator portion 202 is preferably substantially fixed, it will be appreciated that such relative distances can be non-fixed as well. More particularly, upon establishing a first position of FIG. 8D, the carrier seat 302 and the loaded closure element 500″, in the substantially tubular configuration, are disposed proximal and substantially adjacent to the outer surface 620a of the blood vessel wall 620. In this manner, the blood vessel wall 620, adjacent to the opening 610, is disposed substantially between the expanded distal region of the locator portion 202 and the distal end region of the carrier assembly 300.


Hence, once the distal end region of the locator portion 202 properly engages the inner surface 620b of the blood vessel wall 620 as the expansion elements 230 are selectively positioned and moved to the expanded state, the sheath 640 is further retracted proximally, exposing the tongs 402 of the tissue engaging device 400. As mentioned, the interior walls 642 of the sheath 640 cooperate with the garage tube 330 to maintain a substantially cylindrical profile, and to control and operate the use tongs 402 of the distal tissue engaging device, which are substantially distally facing and flush against the tubular body 210 when contained in the sheath 640. Further proximal retraction of the sheath 640 exposes the tongs 402 of the tissue engaging device 400 from inside the sheath lumen 644, allowing the distal tips 404 of the tongs to radially expand toward the engaging condition.


Depending upon the particular design of the tissue engaging device 400, movement of the distal tips 404 of the tongs may occur in different ways. For instance, if the tissue engaging device 400 is composed of a shape memory material, exposure of the heat set tissue engaging device 400 to the tissue environment causes radial expansion of the tongs 402 toward the engaging condition. In contrast, in a resilient, elbowed-type configuration of the engaging device tongs 402, as shown in FIG. 8B-8E, proximal retraction of the reduces the compressive contact of the exterior facing surfaces of the engaging device tongs 402 with the interior wall 642 of the sheath 640. This allows the distal tips 404 of the tongs to radially expand toward the engaging condition.


Once the tissue engaging device 400 has radially expanded to the tissue engaging condition, the garage tube 330 can be axially advanced distally, relative to the carrier assembly 300 and the tissue locator portion 202, maintaining the closure element 500″ seated in the carrier seat 302 (not shown). It will be appreciated, however, that the tube set 305, with the exception of the tubular body 210, can be axially advanced along the tubular body together as a unit, as best viewed in FIG. 8E. Hence, as the cover member is advanced distally, so is the pusher member 320 that unseats the closure element 500″ from the carrier seat 302 about the tubular body 210. Consequently, the distal tips 404 of the tongs, oriented distally toward arterial walls 620′, 620″ that define the vessel opening 610, are extravascularly advanced into piercing or snaring contact therewith. In cooperation with the expansion elements 230 of the distal locator portion 202, in the expanded condition, the arterial walls are maintained taut to facilitate engagement by the tongs.


Referring now to FIG. 8F, the tissue engaging device 400 at the distal end of the garage tube 330 is collapsed together in the closing condition. This is performed by sliding the sheath 640 distally, relative to the carrier assembly 300 and the tissue locator portion 202 (or retracting the garage tube 330 into the sheath 640), increasing contact and engagement of the tongs 402 with the lumen interior wall 642 of the sheath. In effect, the sliding contact pinches the distal tips 404 of the tissue engaging device tongs 402 together, pulling the opposed arterial walls 620′, 620″ radially inward toward the closing condition (i.e., within the first diameter of the closure element).


During operation of the tissue engaging device from the tissue engaging condition to the closing condition, the substantially tubular closure element 500″ is advantageously retained on the outer periphery of the carrier seat 302 by the cover member 330 as illustrated in FIG. 8E. By retaining at least the proximal portion of the substantially tubular closure element 500″ between the distal end region (e.g., the radially, inwardly directed longitudinal extensions 335) of the cover member 330 and the distal end region of the carrier seat 302, the apparatus 100 is configured to provide better tissue penetration for the seated closure element 500″.


As mentioned, in one specific embodiment, the carrier seat 302 and the cover member 330 of the carrier assembly 300 cooperate to maintain the substantially tubular closure element 500″ in the tubular configuration, and fixed relative to the distal tissue engaging device 400. After the tissue engaging device 400 engages the opposed arterial walls 620′, 620″ in the closing condition (FIG. 8F), the locator release system (not shown) can be activated to transition the expansion elements 230 of the tissue locator portion or obturator 202 from the expanded state to the unexpanded state, as shown in FIG. 8G.


The proximal end region of the locator portion 202 can be retracted proximally, effectively retracting the tubular body 210 and the distal locator portion 202 into the lumen 324 of the pusher member 320, and relative to the garage tube 330, closure element 500″ and sheath 640 (FIG. 8G). Simultaneously, the distal end of the pusher member 320 can be advanced distally, contacting the closure element 500″ and advancing it distally and axially along the tubular body 210 of the delivery assembly 100 and toward the tissue locator portion 202. Once the distal end region of the tissue locator portion 202 is axially proximate to the closure element 500″ (e.g., seated about the expansion elements 230 of the tissue locator portion), the closure element is nearly ready to be deployed. The tissue locator portion 202 and the cover member 330 preferably are inhibited from further relative axial movement and remain substantially stationary, relative the handle portion; whereas, the pusher member 320 remains axially slidable. As the pusher member 320 selectively continues distally, the distal end region 320b of the pusher member 320 further engages the substantially tubular closure element 500″ and displaces it from its seating about the expansion elements 230 of the obturator (FIG. 8G).


In accordance with the present invention, the closure element 500″, seated about the delivery assembly 200 in the slightly expanded, substantially tubular condition, is delivered into engagement with the opposed blood vessel arterial wall 620′, 620″ and/or tissue 630 adjacent to the opening 610 without further radial expansion thereof As previously indicated, this benefit is due to the fact that the tissue engaging device 400 is simultaneously engaged with the vessel wall 620, and draws the opposed engaged sides walls 620′, 620″ radially inward relative to one another and within the first diameter of the closure element.


Upon being advanced over the distal locator portion 202, in the unexpanded state, by the pusher member 320, the substantially tubular closure element 500″ is distally deployed as illustrated in FIG. 8G. Continued distal advancement of the pusher member 320 past the distal end of the obturator delivers the tongs 402 of the closure element 500″ into piercing engagement with the arterial walls 620′, 620″ surrounding the vessel opening. When the substantially tubular closure element 500″ is deployed, the tines 520 can pierce and otherwise engage significant amount of the blood vessel wall 620 and/or tissue 630 adjacent to the opening 610 without requiring significant further radio expansion in order to sufficiently engage the walls. Due to the simultaneous engagement of the tissue engaging device 400 with the vessel walls, the tines 520 can engage significant amount of the opposed blood vessel arterial walls 620′, 620″ and/or tissue 630 because the vessel walls 620′, 620″ are pulled together by the engaging device, in the closing condition. In particular, the tongs 402 of the tissue engaging device 400 engage the opposed vessel walls 620′, 620″, and urge them radially inwardly, within the first diameter (and hence within the cross-section 530) of the substantially tubular closure element 500″ simultaneously while the pusher member 320 is deploying the closure element.


Once the substantially tubular closure element 500″ is deployed (FIG. 8H), it begins to transition from the tubular configuration to the natural, planar configuration with opposing tines 520 and a natural cross-section 530 of the closure element 500″. Preferably, the substantially tubular closure element 500″ substantially uniformly transitions from the tubular configuration to the natural, planar configuration. Rotating axially inwardly to form the opposing tines 520 of the closure element 500″, the tines 520 draw the tissue 630 and/or opposing vessel walls 620′, 620″ into the channel 540 of the transitioning closure element 500″. In addition, the tissue 630 is drawn substantially closed and/or sealed as the cross-section 530′ of the substantially tubular closure element 500″ contracts to return to the natural cross-section 530 of the closure element 500. Thereby, the opening 610 in the blood vessel wall 620 can be drawn substantially closed and/or sealed via the closure element 500 as illustrated in FIG. 8H. Subsequently, the sheath 640 and the tube set 305 of the delivery assembly 200 can be withdrawn from the tissue 630.


To reduce interference of the closure element tines 520 with the tissue engaging tongs, while the tongs are engaged with the vessel walls 620′, 620″ in the closing condition, the tips 404 and the tongs 402 can be configured so as to be angularly off-set (at virtually any angle resulting in non-interference) from one another (not shown) about the common longitudinal axis 350. For example, as little as about a 5 degrees angular off-set between the engaging device tongs 402 and the closure element tines 520, about the common longitudinal axis 350, will significantly reduce contact of the tines with the tongs during delivery of the closure element.


Turning now to FIGS. 9 and 10, an alternative embodiment delivery assembly 200 is illustrated wherein the tissue engaging device 400 is disposed within and deployed from a central lumen 204 of the tubular body 210. As indicated above, the primary difference between the various embodiments of the present invention is the location, implementation and execution of the tissue engaging device 400. For example, in this embodiment, the tissue engaging device 400 is configured to intravascularly engage the opposing arterial walls 620′, 620″, while in the previous embodiment, the tissue engaging device extravascularly engages the arterial walls.


The primary orientation and operation of the remaining components of the delivery assembly 200, however, are similar to the previously discussed embodiments. That is, the delivery assembly 200 contains a similar tube set 305 consisting of the locator portion 202 and the carrier assembly 300, the carrier assembly of which is located at the distal end of the tubular body 210, just proximal to the locator portion 202. Briefly, the carrier assembly 300 similarly consists of the carrier seat 302, the tubular pusher member 320 and a nested garage tube 330; the latter of which surrounds the former two, and all of which are coaxial with longitudinal axis 216 of the tubular body 210.


The tissue locator portion 202 includes a tubular bleed back shaft 260 distally extending from a distal end of the carrier seat 302. Preferably, both the carrier seat and the bleed back shaft 260 are integrally formed with one another on the end of the delivery assembly tubular body 210. The bleed back shaft 260 includes a bleed back port 262 that functions to locate the vessel opening 610 at puncture site in the vessel 600. This port 262 is oriented a predetermined distance from the distal end from the bleed back shaft 260. The bleed back port 262 communicates with a bleed back lumen (not shown) that longitudinally extends from the locator portion and through the tubular body 210 of the delivery assembly, although it will be appreciated that the port could also sharing a lumen with the tissue engaging device.


In accordance with this specific embodiment, the cover member or garage tube 330 similarly covers the pusher member 320, the carrier seat 302 of the carrier assembly 300, and the tubular body 210 (i.e., tube set 305). Since the tissue engaging device is not disposed at the distal end of the garage tube, the annular distal end preferably terminates just distal to the carrier seat 302, defining the annular space 360 that seats the closure element 500″ in the substantially tubular configuration. In one preferred embodiment, one or more longitudinal extensions extend distally from the garage tube or cover member 330, similar to extensions 355 of FIG. 7B. Although these longitudinal extensions can extend generally in parallel with common longitudinal axis 350, the longitudinal extensions preferably are biased such that they extend substantially radially inwardly. Thereby, the longitudinal extensions can at least partially close the central lumen 334 substantially adjacent to the distal end region of the cover member 330.


Referring back to FIG. 9, in operation, the tube set 305 of the delivery assembly 200 of the clip applier apparatus 100 is advanced through the sheath lumen 644 of the sheath 640 using similar techniques to those show and described in FIGS. 8A and 8B. When the tissue locator portion 202 locates the vessel opening 610 and the bleed back shaft 260 is inserted into the body vessel 600 to the predefined depth, the bleed back port 262 communicates with fluid flow, hence locating the vessel opening 610.


Once tissue locator portion 202 is properly oriented, the tissue engaging device 400 can be distally deployed from a distal end of the tubular body 210. As shown in FIGS. 10 and 11, the tissue engaging device 400 is slidably disposed within a lumen 204 of the tubular body 210. This lumen 204 further extends through the carrier assembly 300 and the locator portion 202, terminating at an end port 264 at the distal end thereof The tissue engaging device 400 includes one or more tongs 410 having proximal end regions associated with a common control shaft (not shown) operated at the handle portion 380 of the clip applier apparatus 100. Each resilient tong 410 is naturally bowed in a U-shaped manner such that when continually distally advanced from the tubular body end port 264, each tong resiliently bows radially outwardly from common axis 216, and bows upwardly toward the interior surface 620b of the opposing arterial walls 620′, 620″. As the tongs 410 of the tissue engaging device are further deployed, the tips 412 (e.g., barbed tips) of the tongs 410 are configured to intravascularly pierce, snare or grab the arterial walls 620′, 620″ from the underside surface 620b surrounding the puncture site (i.e., in a tissue engaging condition of FIG. 9). The snaring, piercing and/or grabbing of the arterial walls could be accomplished by hooks, barbs, or similar on the ends of the tongs 410. The piercing from the underside surface, furthermore, may be accomplished by the curved shape of the tongs 410 as they exit the distal end of the bleed back shaft 260.


Accordingly, the resilient tongs 410 are sufficiently flexible for sliding reciprocal receipt in the receiving lumen 204 of the tubular body 210 of the delivery assembly 200, yet sufficiently rigid to enable piercing, snaring or grabbing of the arterial walls when engaged therewith. Such materials exhibiting these characteristics, for example, include Nitinol and stainless steel.


Once the opposing arterial walls 620′, 620″ are sufficiently grasped, snared or penetrated, the tubular body 210 of the delivery assembly 200 is retracted extravascularly through the receiving lumen 204 of the pusher member 320. This operation is performed while the garage tube 330, the closure element 500″ and the pusher member 320 are substantially axially maintained at their position relative to the vessel opening 610 of the body vessel 600. Accordingly, the relative movement between the tubular body 210 and the pusher member 320, in turn, unseats the closure element 500″ from the carrier seat 302 and advances it toward the distal end of the tubular body 210. Alone or in combination with the above tubular body retraction, the tongs 410 of the tissue engaging device 400 may also be retracted into the receiving lumen 204 of the tubular body 210. As the tubular body 210 and/or the tongs 410 are being retracted, the arterial walls 620′, 620″ are pulled together radially inward until they are disposed within the first diameter of the closure element 500″, in a closing condition (FIG. 10). Continued retraction further urges the engaged opposing arterial walls 620′, 620″ radially together under the bleed back shaft and into the channel 540 defined by the substantially tubular closure element 500″.


To permit the substantially tubular closure element 500″ to be deployed from the annular cavity 360, the cover member 330 can also be slidably retracted, relative the tubular body 210. The longitudinal extensions 335 of the cover member 330 preferably are sufficiently flexible to expand radially to permit retroactive movement of the distal end region of the cover member 330 peripherally over the mounted closure element 500″. This opens the annular cavity 360 such that the distal end region of the cover member 330 no longer fully encloses the closure element.


Turning now to FIG. 11, the pusher member 320 is then advanced distally to deploy the closure element 500″. Similar to the technique applied above, the tines 520 of the closure element 500″ pierce the opposing arterial walls 620′, 620″ that are radially pulled together, via the tissue engaging device 400 in the closing condition, within the first diameter. Once the substantially tubular closure element 500″ is deployed, it begins to transition from the tubular configuration to the natural, planar configuration with opposing tines 520 and a natural cross-section 530 of the closure element 500 (substantially similar to the deployment of the closure element detailed and shown in FIGS. 8G and 8H). The arterial walls 620′, 620″ are drawn substantially closed and/or sealed as the cross-section 530′ of the substantially tubular closure element 500″ contracts to return to the natural cross-section 530 of the closure element 500. Thereby, the opening 610 in the blood vessel wall 620 can be drawn substantially closed and/or sealed via the closure element 500, as illustrated in FIG. 8H. Subsequently, the tongs 410 of the tissue engaging device 400 are retracted in the bleed back shaft 260, and the delivery assembly 200 and sheath 640 can be removed.


It will be appreciated that the bleed back shaft 260 is composed of a material that reduces sticking of the tines 520 of the closure element during deployment, should any contact ensue. This would be detrimental, of course to the proper clip deployment. Essentially, the composition should be at least as hard as the tines of the closure element so as not to stick into the bleed back shaft itself Beneficial shaft compositions include any hard material that can be formed into a tube and is also biocompatible, such as stainless steel and Nitinol to name a few. Further, similar to the embodiments above-mentioned, the seating of the closure element 500″ about the carrier seat 302 is in a manner angularly off-setting the closure element tines 520 (relative to the longitudinal axis 216) from the angular position of the tissue engaging tongs 410, to reduce interference during deployment of the closure element.



FIGS. 12 and 13 represent another specific embodiment clip applier apparatus 100 incorporating a tissue engaging device 400 that intravascularly engages the opposing arterial walls 620′, 620″. In accordance with this specific embodiment, however, the analogous tongs 410 cooperate to radially push the engaged opposing arterial walls together as opposed to radially pulling them together, as does the embodiment disclosed in FIGS. 9-11. As best illustrated in FIG. 12, the tongs 410 of the tissue engaging device 400, in their natural configuration, are substantially C-shaped. For each tong 410, the respective distal tip 412 is configured to loop nearly all the way around onto itself That is, in their respective own plane substantially intersecting the longitudinal axis 216 of the bleed back shaft 260, the distal tip of each tong loops back around from the end port 264 of the bleed back shaft 260. Briefly, it will be appreciated that natural loop shape of each tong neither needs to be exactly circular, nor be curvilinear for that matter, as long as the tip 412 extends back around in a direction toward the longitudinal axis 216 of the shaft 260.


Again, using similar placement and advancement techniques through the sheath lumen 644 of the sheath 640, as show and described in FIGS. 8A and 8B, the tube set 305 of the delivery assembly 200 can be positioned near the vessel opening 610. Once the tissue locator portion 202, via bleed back port 262, has determined the location and proper depth of insertion of the bleed back shaft 260 into the vessel opening 610 of the vessel body 600, the two or more tongs 410 are advanced distally out of the shaft end port 264, via controls at the handle member 380 (FIG. 6). As the advancement of the tongs 410 of the tissue engaging device 400 distally continue, the tips 412 of the tongs 410 continue to loop back around until they grip, snag and/or partially pierce the underside surface 620b the in opposing arterial walls 620′, 620″ (in a manner similarly described in the operation of the embodiment of FIGS. 9 and 10).


Once the arterial walls 620′, 620″ are sufficiently initially engaged, further advancement of the tongs from the distal end port 264 of the bleed back shaft 260 causes the tong tips 412 to return to their natural state, in their respective plane (i.e., directed back toward longitudinal axis 216 of the bleed back shaft 260). In effect, the engaged opposed arterial walls 620′, 620″ are pushed together by the advancing tong tips 412, which return to their natural state, until the edges 622′, 622″ of the opposing arterial walls 620′, 620″ contact the exterior surface of the bleed back shaft 260. Accordingly, unlike the previous embodiment, the engaged opposing arterial walls 620′, 620″ are urged together without retracting the bleed back shaft 260 and/or retracting the tongs 410 back into the receiving lumen 204. This is beneficial in that it allows the user to continue monitoring the proper location of the device. Further, by not retracting the tongs, the chance that the tongs dislodge from the arterial walls decreases prior to deployment of the closure element.


Accordingly, the tips 412 of the respective tongs 410 are configured to not fully penetrate the engaged opposing arterial wall 620′, 620″ or each tong may experience difficulty urging and pushing the opposing walls back toward and against the bleed back shaft. For example, the tip configuration can be more blunted, radiused or roughened, so as to partially pierce the tissue, but not fully penetrate it.


Regarding the resilient tongs 410, they must be capable of sufficient flexibility to unfold from their naturally curved and hooked configuration to a substantially straight configuration when housed or stored within the lumen 204 of the tubular body 210. However, the tongs 410 of the tissue engaging device 400 must also be sufficiently stiff, strong and resilient to push the engaged arterial walls together, and back against the bleed back shaft 260 when the tongs are fully deployed from the distal end of the bleed back shaft 260. Such materials for each tong 410, for example, may include Nitinol and stainless steel.


Since the opposed arterial walls 620′, 620″ must be pushed, as opposed to pulled, radially together to an orientation within the first diameter of the seated closure element 500″, the diameter of the bleed back shaft 260 at the region of contact by the edge 622′, 622″ of the arterial walls 620′, 620″ is reduced from that of the carrier seat 302. Such a diameter reduction, relative to the carrier seat, increases the width of tissue engagement about by the tines 520 of the closure element 500″, about the vessel opening 610, by enabling the opposed arterial walls to be pushed closer together.


Referring now to FIG. 14, the pusher member 320 may be distally advanced to engage the seated closure element 500″, in the substantially tubular condition, during deployment. The delivery assembly 200, and hence the bleed back shaft 260, are axially maintained in position during the deployment of the closure element 500″. Once the substantially tubular closure element 500″ is deployed, it begins to transition from the tubular configuration to the natural, planar configuration with opposing tines 520 and a natural cross-section 530 of the closure element 500 (substantially similar to the deployment of the closure element detailed and shown in FIGS. 8G and 8H). Again, the opening 610 in the blood vessel wall 620 can be drawn substantially closed and/or sealed via the closure element 500″ as illustrated in FIG. 8H. Subsequently, the tongs 410 of the tissue engaging device 400 are the retracted in the bleed back shaft 260, and then the bleed back shaft 260 is retracted from the “closed” opening 610 of the puncture site.


It will again be appreciated that the bleed back shaft 260 is composed of a material that reduces sticking of the tines 520 of the closure element therewith during deployment and withdrawal of the shaft from the opening, should any contact ensue. As mentioned above, beneficial shaft compositions include any hard material that can be formed into a tube and is also biocompatible, such as Nitinol and Stainless steel. Furthermore, the seating of the closure element 500″ about the carrier seat 302 is in a manner angularly off-setting the closure element tines 520 (relative to the longitudinal axis 216) from the angular position of the tissue engaging tongs 410, to reduce interference during deployment of the closure element.


Referring now to FIG. 15, another specific embodiment of the clip applier apparatus 100 is illustrated that is structurally and functionally similar to the clip applier apparatus embodiment detailed in FIGS. 9-11. In this specific embodiment, however, the cover member or garage tube 330 shown in the embodiment of FIG. 9 is removed, providing a significantly reduced diametric footprint for the tube set 305 of the delivery assembly 200. Accordingly, during advancement of the delivery assembly to the vessel opening 610, via the lumen 644 of the sheath 640, protection of the seated closure element 500″ is afforded by the sheath itself.


As above-mentioned, the diametric footprint of the clip applier apparatus 100 in this specific embodiment is further reduced by an amount equivalent to the removal of the garage tube from the tube set 305. Hence, the tube set 305 of the delivery assembly only includes the pusher member 320 of the carrier assembly 300, and the tubular body 210. The tubular body 210, which supports the carrier seat 302, the tissue locator assembly 202 and the tissue engaging device 400 supported within the receiving tubular body lumen 204, may similarly be capable of axial displacement, relative to the sheath 640, the pusher member 320 and the closure element 500″, in the substantially tubular configuration.


Furthermore, the introducer sheath 640 will selected to cooperate with the tube set 305 of the delivery assembly 200 in a manner similar to the cooperation between the garage tube 330 and the pusher member 302 and closure element 500″ of the previous embodiments. That is, the interior diameter of the sheath lumen 644 should be sized to cooperate with the exterior diameter of the pusher member 320 and the seated closure element 500″ to permit sliding axial displacement therebetween, yet be sufficiently snug at the distal tip to retain the closure element in the substantially tubular configuration until it is released out of its distal thereof.


Referring back to FIG. 15, the tissue engaging device 400 of this embodiment is illustrated incorporating a similar device to that described in the embodiment of FIGS. 9-11 (i.e., centrally deployed resilient tongs 410). It will be appreciated, however, that any tissue engaging device could be incorporated that is functionally capable of engaging and urging the opposed arterial walls 620′, 620″ together and radially within the first diameter of the closure element 500″ (about longitudinal axis 216).


Again, similar to the operation of the embodiment of FIGS. 9-11, once the tissue locator portion 202 is properly oriented, the tissue engaging device 400 can be distally deployed from a distal end of the tubular body 210. The tissue engaging device 400 includes one or more tongs 410 having proximal end regions associated with a common control shaft (not shown) operated at the handle portion of the clip applier apparatus 100. Each resilient tong 410 is naturally bowed in a U-shaped manner such that when continually distally advanced from the tubular body end port 264, each tong resiliently bows radially outwardly from common axis 216, and bows upwardly toward the interior surface 620b of the opposing arterial walls 620′, 620″. Once the tongs 410 of the tissue engaging device are sufficiently anchored to the corresponding arterial walls 620′, 620″ (in the tissue engaging condition similar to that shown in FIG. 9), the tubular body 210 and/or the tongs 410 are retracted, while the pusher member 320 and the closure element 500″ are substantially maintained, axially. Similar to the closing condition of FIG. 10 and as shown in FIG. 15, the engaged opposing arterial walls 620′, 620″ are drawn and urged together, radially inward toward one another until they are disposed within the first diameter of the closure element 500″. Continued retraction further urges the engaged opposing arterial walls 620′, 620″ radially together under the bleed back shaft and into the channel 540 defined by the substantially tubular closure element 500″.


The pusher member 320 is then advanced distally to deploy the closure element 500″ off of the end of the obturator or tissue locator device 202, and out of the lumen 644 of the introducer sheath 640. The distally directed tines 520 of the closure element 500″ pierce the opposing arterial walls 620′, 620″ that are radially pulled together, via the tissue engaging device 400 in the closing condition, within the first diameter. Once the substantially tubular closure element 500″ is deployed, it begins to transition from the tubular configuration to the natural, planar configuration with opposing tines 520 and a natural cross-section 530 of the closure element 500 (substantially similar to the deployment of the closure element detailed and shown in FIGS. 8G and 8H). The arterial walls 620′, 620″ are thus drawn substantially closed and/or sealed. Subsequently, the tongs 410 of the tissue engaging device 400 are retracted in the bleed back shaft 260, and the delivery assembly 200 and sheath 640 can be removed.


The present invention has been described using various element identifiers to represent elements in the figures. It should be considered that the element identifiers described in connection with a particular figure may be shown in a different figure for purposes of clarity. Thus, the element identifies described in connection to a particular figure may be illustrated in a different figure for clarity because the same element identifiers have been used to describe the same elements.


The invention is susceptible to various modifications, alternative forms and uses, and specific examples thereof have been shown by way of example in the drawings and are herein described in detail. For instance, while the present invention has been primarily described for use in vessel closure, it will be appreciated that the present invention may be suitable for other repair applications as well, such as for patent foramina ovalia (PFO) application. Other modifications may include a guide wire lumen so that the distal ends may be positioned over a guide wire as well. It should be understood, however, that the invention is not to be limited to the particular forms or methods disclosed, but to the contrary, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the claims.


The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description.

Claims
  • 1. A closure system for closing an opening formed in a body lumen perimeterically defined by opposing arterial walls, said system comprising: a closure element adapted to deform from a natural, substantially resilient planar configuration to a substantially tubular configuration, having a substantially natural transverse cross-sectional dimension;a delivery assembly positionable through said tissue and into the opening in the body lumen, and having an elongated body, a carrier assembly and a distal tissue engaging device, said carrier assembly configured to be slidably received in a lumen of an introducer sheath, said carrier assembly including a carrier seat configured to carry and peripherally support said closure element in the substantially tubular configuration, in a first diameter, and said distal tissue engaging device selectably axially displaceable relative to said carrier seat between an engaging condition, in which said distal tissue engaging device is configured to engage the opposing arterial walls of said body lumen adjacent to said opening, and a closing condition, in which said distal tissue engaging device is configured to urge the engaged opposing arterial walls substantially transversely together such that the closure element can be deployed from the carrier assembly, while substantially maintained in the first diameter, into the opposing arterial walls, said distal tissue engaging device including two or more opposed engaging tongs having respective tips, said two or more tongs being configured to resiliently move radially outwardly from a longitudinal axis of the carrier assembly to extend said respective tips outwardly beyond an outer diameter of the carrier seat, wherein the tissue engaging device is configured to cooperate with the introducer sheath to enable movement of said two or more tongs between the engaging condition, with said two or more tongs resiliently moving radially outwardly to the engaging condition, and the closing condition and the closure element being configured to be deployed between said two or more tongs; anda pusher member slidably disposed about said elongated body for relative axial sliding displacement therebetween, said pusher member having a contact portion disposed proximally adjacent the closure element to selectively distally deploy said closure element from said carrier assembly, in the substantially tubular configuration, to engage said opposing arterial walls and to return to said natural, substantially planar configuration and said natural, transverse cross-sectional dimension such that the engaged opposing arterial walls are drawn substantially closed.
  • 2. The apparatus of claim 1, wherein said two or more opposed engaging tongs having respective end tips are configured to open radially in directions extending beyond the outer diameter to initially engage the opposing portions of the arterial wall, in the engaging condition.
  • 3. The apparatus of claim 1, wherein said carrier assembly having a cover member, said cover member being configured to protect at least said closure element which is contained therein.
  • 4. The apparatus of claim 3, wherein said distal tissue engaging device is integral with a distal end of said cover member.
  • 5. The apparatus of claim 1, wherein said carrier assembly is formed and dimensioned for sliding axial, reciprocating, receipt in a lumen of the introducer sheath extending through said tissue and terminating proximate the opening, wherein distal retraction of the introducer sheath exposes said two or more tongs to allow the tips to extend to the tissue engaging position and distal sliding of the introducer sheath moves said two or more tongs to the closing condition.
  • 6. The apparatus of claim 1, further comprising a locator to position the carrier assembly and distal tissue engaging device adjacent to the opening in the body lumen, the locator having a distal locator portion selectably controllable between an unexpanded state and an expanded state for engaging the opposing portions of the arterial wall of said body lumen.
  • 7. The apparatus of claim 1, further including a distal tissue locator portion contained on said delivery assembly, and configured to facilitate detection of the body lumen, said distal locator portion including one or more expansion elements configured to expand substantially transversely with respect to a longitudinal axis of the distal locator portion.
  • 8. The apparatus of claim 7, wherein said distal locator portion is selectably controllable between an unexpanded state and an expanded state for engaging said opposing arterial walls of said body lumen.
  • 9. The apparatus of claim 8 wherein in said unexpanded state, said distal locator portion has a transverse cross-sectional dimension less than that of said opening, and in said expanded state, said distal locator portion has a transverse cross-sectional dimension greater than or substantially equal to that of said opening.
  • 10. The closure system of claim 1, wherein said pusher member comprises one or more distally extending longitudinal extensions.
  • 11. The closure system of claim 1, further comprising a locator slidably receivable within said pusher member and said delivery assembly.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to and the benefit of U.S. Provisional Patent Application No. 60/843,325, filed Sep. 8, 2006, entitled “APPARATUS AND METHOD FOR DELIVERING A CLOSURE ELEMENT,” the disclosure of which is incorporated herein in its entirety by specific reference.

US Referenced Citations (924)
Number Name Date Kind
287046 Norton Oct 1883 A
438400 Brennen Oct 1890 A
556082 Boeddinghaus Mar 1896 A
1088393 Backus Feb 1914 A
1242139 Callahan Oct 1917 A
1331401 Summers Feb 1920 A
1480935 Gleason Jan 1924 A
1596004 De Bengoa Aug 1926 A
1647958 Ciarlante Nov 1927 A
1880569 Weis Oct 1932 A
2087074 Tucker Jul 1937 A
2210061 Caminez Aug 1940 A
2254620 Miller Sep 1941 A
2316297 Southerland et al. Apr 1943 A
2371978 Perham Mar 1945 A
2453227 James Nov 1948 A
2583625 Bergan Jan 1952 A
2684070 Kelsey Jul 1954 A
2755699 Forster Jul 1956 A
2910067 White Oct 1959 A
2944311 Schneckenberger Jul 1960 A
2951482 Sullivan Sep 1960 A
2969887 Darmstadt et al. Jan 1961 A
3015403 Fuller Jan 1962 A
3113379 Frank Dec 1963 A
3120230 Skold Feb 1964 A
3142878 Santora Aug 1964 A
3029754 Brown Oct 1965 A
3348595 Stevens, Jr. Oct 1967 A
3357070 Sloan Dec 1967 A
3482428 Kapitanov et al. Dec 1969 A
3494533 Green et al. Feb 1970 A
3510923 Blake May 1970 A
3523351 Filia Aug 1970 A
3586002 Wood Jun 1971 A
3604425 Le Roy Sep 1971 A
3618447 Goins Nov 1971 A
3677243 Nerz Jul 1972 A
3682180 McFarlane Aug 1972 A
3757629 Schneider Sep 1973 A
3805337 Branstetter Apr 1974 A
3823719 Cummings Jul 1974 A
3828791 Santos Aug 1974 A
3856016 Davis Dec 1974 A
3874388 King et al. Apr 1975 A
3908662 Razgulov et al. Sep 1975 A
3926194 Greenberg et al. Dec 1975 A
3939820 Grayzel Feb 1976 A
3944114 Coppens Mar 1976 A
3960147 Murray Jun 1976 A
3985138 Jarvik Oct 1976 A
4007743 Blake Feb 1977 A
4014492 Rothfuss Mar 1977 A
4018228 Goosen Apr 1977 A
4047533 Perciaccante et al. Sep 1977 A
4064881 Meredith Dec 1977 A
4112944 Williams Sep 1978 A
4153321 Pombrol May 1979 A
4162673 Patel Jul 1979 A
4169476 Hiltebrandt Oct 1979 A
4189808 Brown Feb 1980 A
4192315 Hilzinger et al. Mar 1980 A
4201215 Crossett et al. May 1980 A
4204541 Kapitanov May 1980 A
4207870 Eldridge Jun 1980 A
4214587 Sakura, Jr. Jul 1980 A
4215699 Patel Aug 1980 A
4217902 March Aug 1980 A
4267995 McMillan May 1981 A
4273129 Boebel Jun 1981 A
4274415 Kanamoto et al. Jun 1981 A
4278091 Borzone Jul 1981 A
4317445 Robinson Mar 1982 A
4317451 Cerwin et al. Mar 1982 A
4318401 Zimmerman Mar 1982 A
4327485 Rix May 1982 A
4345606 Littleford Aug 1982 A
4359052 Staub Nov 1982 A
4368736 Kaster Jan 1983 A
4396139 Hall et al. Aug 1983 A
4407286 Noiles et al. Oct 1983 A
4411654 Boarini et al. Oct 1983 A
4412832 Kling et al. Nov 1983 A
4428376 Mericle Jan 1984 A
4440170 Golden et al. Apr 1984 A
4449531 Cerwin et al. May 1984 A
4475544 Reis Oct 1984 A
4480356 Martin Nov 1984 A
4485816 Krumme Dec 1984 A
RE31855 Osborne Mar 1985 E
4505273 Braun et al. Mar 1985 A
4505274 Speelman Mar 1985 A
4523591 Kaplan et al. Jun 1985 A
4523695 Braun et al. Jun 1985 A
4525157 Valaincourt Jun 1985 A
4526174 Froehlich Jul 1985 A
4586503 Kirsch et al. May 1986 A
4592498 Braun et al. Jun 1986 A
4596559 Fleischhacker Jun 1986 A
4607638 Crainich Aug 1986 A
4610251 Kumar Sep 1986 A
4610252 Catalano Sep 1986 A
4635634 Santos Jan 1987 A
4651737 Deniega Mar 1987 A
4664305 Blake, III et al. May 1987 A
4665906 Jervis May 1987 A
4687469 Osypka Aug 1987 A
4693249 Schenck et al. Sep 1987 A
4697312 Freyer Oct 1987 A
4719917 Barrows et al. Jan 1988 A
4724840 McVay et al. Feb 1988 A
4738658 Magro et al. Apr 1988 A
4744364 Kensey May 1988 A
4747407 Liu et al. May 1988 A
4759364 Boebel Jul 1988 A
4771782 Millar Sep 1988 A
4772266 Groshong Sep 1988 A
4777950 Kees, Jr. Oct 1988 A
4789090 Blake, III Dec 1988 A
4832688 Sagae et al. May 1989 A
4836204 Landymore et al. Jun 1989 A
4852568 Kensey Aug 1989 A
4860746 Yoon Aug 1989 A
4865026 Barrett Sep 1989 A
4874122 Froelich et al. Oct 1989 A
4878915 Brantigan Nov 1989 A
4885003 Hillstead Dec 1989 A
4886067 Palermo Dec 1989 A
4887601 Richards Dec 1989 A
4890612 Kensey Jan 1990 A
4902508 Badylak et al. Feb 1990 A
4917087 Walsh et al. Apr 1990 A
4917089 Sideris Apr 1990 A
4929240 Kirsch et al. May 1990 A
4934364 Green Jun 1990 A
4950258 Kawai et al. Aug 1990 A
4957499 Lipatov et al. Sep 1990 A
4961729 Vaillancourt Oct 1990 A
4967949 Sandhaus Nov 1990 A
4976721 Blasnik et al. Dec 1990 A
4983176 Cushman et al. Jan 1991 A
4997436 Oberlander Mar 1991 A
4997439 Chen Mar 1991 A
5002562 Oberlander Mar 1991 A
5007921 Brown Apr 1991 A
5015247 Michelson May 1991 A
5021059 Kensey et al. Jun 1991 A
5026390 Brown Jun 1991 A
5030226 Green et al. Jul 1991 A
5032127 Frazee et al. Jul 1991 A
5035692 Lyon et al. Jul 1991 A
5047047 Yoon Sep 1991 A
5053008 Bajaj Oct 1991 A
5059201 Asnis Oct 1991 A
5061274 Kensey Oct 1991 A
5078731 Hayhurst Jan 1992 A
5092941 Miura Mar 1992 A
5100418 Yoon et al. Mar 1992 A
5100422 Berguer et al. Mar 1992 A
5108420 Marks Apr 1992 A
5108421 Fowler Apr 1992 A
5114032 Laidlaw May 1992 A
5114065 Storace May 1992 A
5116349 Aranyi May 1992 A
5122122 Allgood Jun 1992 A
5122156 Granger et al. Jun 1992 A
5131379 Sewell, Jr. Jul 1992 A
5141520 Goble et al. Aug 1992 A
5147381 Heimerl et al. Sep 1992 A
5156609 Nakao et al. Oct 1992 A
5163343 Gish Nov 1992 A
5167634 Corrigan, Jr. et al. Dec 1992 A
5167643 Lynn Dec 1992 A
5171249 Stefanchik et al. Dec 1992 A
5171250 Yoon Dec 1992 A
5176648 Holmes et al. Jan 1993 A
5192288 Thompson et al. Mar 1993 A
5192300 Fowler Mar 1993 A
5192301 Kamiya et al. Mar 1993 A
5192302 Kensey et al. Mar 1993 A
5192602 Spencer et al. Mar 1993 A
5193533 Body et al. Mar 1993 A
5197971 Bonutti Mar 1993 A
5207697 Carusillo et al. May 1993 A
5209756 Seedhorm et al. May 1993 A
5217024 Dorsey et al. Jun 1993 A
5222974 Kensey et al. Jun 1993 A
5226908 Yoon Jul 1993 A
5236435 Sewell, Jr. Aug 1993 A
5242456 Nash et al. Sep 1993 A
5242457 Akopov et al. Sep 1993 A
5242459 Buelna Sep 1993 A
5246156 Rothfuss et al. Sep 1993 A
5246443 Mai Sep 1993 A
5250058 Miller et al. Oct 1993 A
5254105 Haaga Oct 1993 A
5255679 Imran Oct 1993 A
5269792 Kovac et al. Dec 1993 A
5275616 Fowler Jan 1994 A
5281422 Badylak et al. Jan 1994 A
5282808 Kovac et al. Feb 1994 A
5282827 Kensey et al. Feb 1994 A
5289963 McGarry et al. Mar 1994 A
5290243 Chodorow et al. Mar 1994 A
5290310 Makower et al. Mar 1994 A
5292309 Van Tassel et al. Mar 1994 A
5292332 Lee Mar 1994 A
5304183 Gourlay et al. Apr 1994 A
5304184 Hathaway et al. Apr 1994 A
5304204 Bregen Apr 1994 A
5306254 Nash et al. Apr 1994 A
5309927 Welch May 1994 A
5318542 Hirsch et al. Jun 1994 A
5320639 Rudnick Jun 1994 A
5327908 Gerry Jul 1994 A
5330445 Haaga Jul 1994 A
5330503 Yoon Jul 1994 A
5334216 Vidal et al. Aug 1994 A
5334217 Das Aug 1994 A
5335680 Moore Aug 1994 A
5340360 Stefanchik Aug 1994 A
5342393 Stack Aug 1994 A
5344439 Otten Sep 1994 A
5350399 Erlebacher et al. Sep 1994 A
5352229 Goble et al. Oct 1994 A
5364406 Sewell, Jr. Nov 1994 A
5364408 Gordon Nov 1994 A
5366458 Korthoff et al. Nov 1994 A
5366479 McGarry et al. Nov 1994 A
5383896 Gershony et al. Jan 1995 A
5383897 Wholey Jan 1995 A
RE34866 Kensey et al. Feb 1995 E
5392978 Velez Feb 1995 A
5395030 Kuramoto et al. Mar 1995 A
5404621 Heinke Apr 1995 A
5411520 Nash et al. May 1995 A
5413571 Katsaros et al. May 1995 A
5413584 Schulze May 1995 A
5416584 Kay May 1995 A
5417699 Klein et al. May 1995 A
5419765 Weldon et al. May 1995 A
5419777 Hofling May 1995 A
5421832 Lefebvre Jun 1995 A
5423857 Rosenman et al. Jun 1995 A
5425489 Shichman et al. Jun 1995 A
5425740 Hutchinson, Jr. Jun 1995 A
5431639 Shaw Jul 1995 A
5431667 Thompson et al. Jul 1995 A
5433721 Hooven et al. Jul 1995 A
5437631 Janzen Aug 1995 A
5439479 Shichman et al. Aug 1995 A
5443477 Marin et al. Aug 1995 A
5443481 Lee Aug 1995 A
5445167 Yoon et al. Aug 1995 A
5449359 Groiso Sep 1995 A
5451235 Lock et al. Sep 1995 A
5456400 Shichman et al. Oct 1995 A
5462561 Voda Oct 1995 A
5464413 Siska, Jr. et al. Nov 1995 A
5466241 Leroy et al. Nov 1995 A
5470010 Rothfuss et al. Nov 1995 A
5471982 Edwards et al. Dec 1995 A
5474557 Mai Dec 1995 A
5474569 Zinreich et al. Dec 1995 A
5476505 Limon Dec 1995 A
5478352 Fowler Dec 1995 A
5478353 Yoon Dec 1995 A
5478354 Tovey et al. Dec 1995 A
5486195 Myers et al. Jan 1996 A
5497933 DeFonzo et al. Mar 1996 A
5507744 Tay et al. Apr 1996 A
5507755 Gresl et al. Apr 1996 A
5522840 Krajicek Jun 1996 A
5527322 Klein et al. Jun 1996 A
5536251 Evard et al. Jul 1996 A
5540712 Kleshinski et al. Jul 1996 A
5540716 Hlavacek Jul 1996 A
5544802 Crainich Aug 1996 A
5547474 Kloeckl et al. Aug 1996 A
5560532 DeFonzo et al. Oct 1996 A
5571120 Yoon Nov 1996 A
5573784 Badylak et al. Nov 1996 A
5575771 Walinsky Nov 1996 A
5582616 Bolduc et al. Dec 1996 A
5584879 Reimold et al. Dec 1996 A
5591205 Fowler Jan 1997 A
5593412 Martinez et al. Jan 1997 A
5601602 Fowler Feb 1997 A
5609597 Lehrer Mar 1997 A
5613974 Andreas et al. Mar 1997 A
5618291 Thompson et al. Apr 1997 A
5620452 Yoon Apr 1997 A
5620461 Muijs et al. Apr 1997 A
5626614 Hart May 1997 A
5634936 Lindon et al. Jun 1997 A
5643318 Tsukernik et al. Jul 1997 A
5645565 Rudd et al. Jul 1997 A
5645566 Brenneman et al. Jul 1997 A
5645567 Crainich Jul 1997 A
5649959 Hannam et al. Jul 1997 A
D383539 Croley Sep 1997 S
5669935 Rosenman et al. Sep 1997 A
5674231 Green et al. Oct 1997 A
5676689 Kensey et al. Oct 1997 A
5676974 Valdes et al. Oct 1997 A
5681280 Rusk et al. Oct 1997 A
5681334 Evans et al. Oct 1997 A
5683405 Yacoubian et al. Nov 1997 A
5690674 Diaz Nov 1997 A
5695504 Gifford, III et al. Dec 1997 A
5695505 Yoon Dec 1997 A
5695524 Kelley et al. Dec 1997 A
5700273 Buelna et al. Dec 1997 A
5709224 Behl et al. Jan 1998 A
5713899 Marnay et al. Feb 1998 A
5715987 Kelley et al. Feb 1998 A
5716375 Fowler Feb 1998 A
5720755 Dakov Feb 1998 A
5725498 Janzen et al. Mar 1998 A
5725552 Kotula et al. Mar 1998 A
5725554 Simon et al. Mar 1998 A
5728110 Vidal et al. Mar 1998 A
5728114 Evans et al. Mar 1998 A
5728116 Rosenman Mar 1998 A
5728122 Leschinsky et al. Mar 1998 A
5728132 Van Tassel et al. Mar 1998 A
5728133 Kontos Mar 1998 A
5732872 Bolduc et al. Mar 1998 A
5735736 Volk Apr 1998 A
5735873 MacLean Apr 1998 A
5749826 Faulkner May 1998 A
5752966 Chang May 1998 A
5755726 Pratt et al. May 1998 A
5755778 Kleshinski May 1998 A
5766217 Christy Jun 1998 A
5766246 Mulhauser et al. Jun 1998 A
5769870 Salahieh et al. Jun 1998 A
5776147 Dolendo Jul 1998 A
5779707 Bertholet et al. Jul 1998 A
5780807 Saunders Jul 1998 A
5782844 Yoon et al. Jul 1998 A
5782860 Epstein et al. Jul 1998 A
5782861 Cragg et al. Jul 1998 A
5795958 Rao et al. Aug 1998 A
5797928 Kogasaka Aug 1998 A
5797931 Bito et al. Aug 1998 A
5797933 Snow et al. Aug 1998 A
5797958 Yoon Aug 1998 A
5797960 Stevens et al. Aug 1998 A
5810776 Bacich et al. Sep 1998 A
5810846 Virnich et al. Sep 1998 A
5810851 Yoon Sep 1998 A
5817113 Gifford, III et al. Oct 1998 A
5820631 Nobles Oct 1998 A
5827298 Hart et al. Oct 1998 A
5830125 Scribner et al. Nov 1998 A
5830221 Stein et al. Nov 1998 A
5833698 Hinchliffe et al. Nov 1998 A
5843167 Dwyer et al. Dec 1998 A
5845657 Carberry et al. Dec 1998 A
5853421 Leschinsky et al. Dec 1998 A
5853422 Huebsch et al. Dec 1998 A
5855312 Toledano Jan 1999 A
5858082 Cruz et al. Jan 1999 A
5860991 Klein et al. Jan 1999 A
5861003 Latson et al. Jan 1999 A
5861005 Kontos Jan 1999 A
5868755 Kanner et al. Feb 1999 A
5868762 Cragg et al. Feb 1999 A
5868763 Spence et al. Feb 1999 A
5871474 Hermann et al. Feb 1999 A
5871501 Leschinsky et al. Feb 1999 A
5871525 Edwards et al. Feb 1999 A
5873876 Christy Feb 1999 A
5873891 Sohn Feb 1999 A
5879366 Shaw et al. Mar 1999 A
5891088 Thompson et al. Apr 1999 A
5897487 Ouchi Apr 1999 A
5902310 Foerster et al. May 1999 A
5904697 Gifford, III et al. May 1999 A
5906631 Imran May 1999 A
5907893 Zadno-Azizi et al. Jun 1999 A
5910155 Ratcliff et al. Jun 1999 A
5919207 Taheri Jul 1999 A
5922009 Epstein et al. Jul 1999 A
5928231 Klein et al. Jul 1999 A
5928251 Aranyi et al. Jul 1999 A
5935147 Kensey et al. Aug 1999 A
5938667 Peyser et al. Aug 1999 A
5941890 Voegele et al. Aug 1999 A
5947999 Groiso Sep 1999 A
5948001 Larsen Sep 1999 A
5951518 Licata et al. Sep 1999 A
5951575 Bolduc et al. Sep 1999 A
5951576 Wakabayashi Sep 1999 A
5951589 Epstein et al. Sep 1999 A
5954732 Hart et al. Sep 1999 A
5957900 Ouchi Sep 1999 A
5957936 Yoon et al. Sep 1999 A
5957938 Zhu et al. Sep 1999 A
5957940 Tanner et al. Sep 1999 A
5964782 Lafontaine et al. Oct 1999 A
5976161 Kirsch et al. Nov 1999 A
5976174 Ruiz Nov 1999 A
5984934 Ashby et al. Nov 1999 A
5984948 Hasson Nov 1999 A
5984949 Levin Nov 1999 A
5993468 Rygaard Nov 1999 A
5993476 Groiso Nov 1999 A
6001110 Adams Dec 1999 A
6004341 Zhu et al. Dec 1999 A
6007563 Nash et al. Dec 1999 A
6010517 Baccaro Jan 2000 A
6013084 Ken et al. Jan 2000 A
6015815 Mollison Jan 2000 A
6019779 Thorud et al. Feb 2000 A
6022372 Kontos Feb 2000 A
6024750 Mastri Feb 2000 A
6024756 Huebsch et al. Feb 2000 A
6030364 Durgin et al. Feb 2000 A
6030413 Lazarus Feb 2000 A
6033427 Lee Mar 2000 A
6036703 Evans et al. Mar 2000 A
6036720 Abrams et al. Mar 2000 A
6045570 Epstein et al. Apr 2000 A
6048358 Barak Apr 2000 A
6056768 Cates et al. May 2000 A
6056769 Epstein et al. May 2000 A
6056770 Epstein et al. May 2000 A
6059800 Hart et al. May 2000 A
6059825 Hobbs et al. May 2000 A
6063085 Tay et al. May 2000 A
6063114 Nash et al. May 2000 A
6071300 Brenneman et al. Jun 2000 A
6077281 Das Jun 2000 A
6077291 Das Jun 2000 A
6080182 Shaw et al. Jun 2000 A
6080183 Tsugita et al. Jun 2000 A
6083242 Cook Jul 2000 A
6090130 Nash et al. Jul 2000 A
6095155 Criscuolo Aug 2000 A
6102271 Longo et al. Aug 2000 A
6110184 Weadock Aug 2000 A
6113610 Poncet Sep 2000 A
6113612 Swanson et al. Sep 2000 A
6117125 Rothbarth et al. Sep 2000 A
6117148 Ravo Sep 2000 A
6117157 Tekulve Sep 2000 A
6117159 Huebsch et al. Sep 2000 A
6120513 Bailey et al. Sep 2000 A
6120524 Taheri Sep 2000 A
6126675 Schervinsky et al. Oct 2000 A
6136010 Modesitt et al. Oct 2000 A
6146385 Torrie et al. Nov 2000 A
6149660 Laufer et al. Nov 2000 A
6149667 Hovland et al. Nov 2000 A
6152144 Lesh et al. Nov 2000 A
6152936 Christy et al. Nov 2000 A
6152937 Peterson et al. Nov 2000 A
6161263 Anderson Dec 2000 A
6165204 Levinson et al. Dec 2000 A
6171277 Ponzi Jan 2001 B1
6171329 Shaw et al. Jan 2001 B1
6174322 Schneidt Jan 2001 B1
6179849 Yencho et al. Jan 2001 B1
6179860 Fulton, III et al. Jan 2001 B1
6193708 Ken et al. Feb 2001 B1
6193734 Bolduc et al. Feb 2001 B1
6197042 Ginn et al. Mar 2001 B1
6198974 Webster, Jr. Mar 2001 B1
6200329 Fung et al. Mar 2001 B1
6200330 Benderev et al. Mar 2001 B1
6206895 Levinson Mar 2001 B1
6206913 Yencho et al. Mar 2001 B1
6206931 Cook et al. Mar 2001 B1
6210407 Webster Apr 2001 B1
6220248 Voegele et al. Apr 2001 B1
6221102 Baker et al. Apr 2001 B1
6231561 Frazier et al. May 2001 B1
6245079 Nobles et al. Jun 2001 B1
6248124 Pedros et al. Jun 2001 B1
6254617 Spence et al. Jul 2001 B1
6254642 Taylor Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6267773 Gadberry et al. Jul 2001 B1
6273903 Wilk Aug 2001 B1
6277140 Ginn et al. Aug 2001 B2
6280460 Bolduc et al. Aug 2001 B1
6287322 Zhu et al. Sep 2001 B1
6296657 Brucker Oct 2001 B1
6302870 Jacobsen et al. Oct 2001 B1
6302898 Edwards et al. Oct 2001 B1
6305891 Burlingame Oct 2001 B1
6309416 Swanson et al. Oct 2001 B1
6319258 McAllen, III et al. Nov 2001 B1
6322580 Kanner Nov 2001 B1
6328727 Frazier et al. Dec 2001 B1
6329386 Mollison Dec 2001 B1
6334865 Redmond et al. Jan 2002 B1
6348064 Kanner Feb 2002 B1
6355052 Neuss et al. Mar 2002 B1
6358258 Arcia et al. Mar 2002 B1
6375671 Kobayashi et al. Apr 2002 B1
D457958 Dycus May 2002 S
6383208 Sancoff et al. May 2002 B1
6391048 Ginn et al. May 2002 B1
6395015 Borst et al. May 2002 B1
6398752 Sweezer et al. Jun 2002 B1
6402765 Monassevitch et al. Jun 2002 B1
6409739 Nobles et al. Jun 2002 B1
6419669 Frazier et al. Jul 2002 B1
6421899 Zitnay Jul 2002 B1
6423054 Ouchi Jul 2002 B1
6425911 Akerfeldt et al. Jul 2002 B1
6428472 Haas Aug 2002 B1
6428548 Durgin et al. Aug 2002 B1
6443158 Lafontaine et al. Sep 2002 B1
6443963 Baldwin et al. Sep 2002 B1
6447540 Fontaine et al. Sep 2002 B1
6450391 Kayan et al. Sep 2002 B1
6458130 Frazier et al. Oct 2002 B1
6461364 Ginn et al. Oct 2002 B1
6482224 Michler et al. Nov 2002 B1
6488692 Spence et al. Dec 2002 B1
6500115 Krattiger et al. Dec 2002 B2
6506210 Kanner Jan 2003 B1
6508828 Akerfeldt et al. Jan 2003 B1
6514280 Gilson Feb 2003 B1
6517555 Caro Feb 2003 B1
6517569 Mikus et al. Feb 2003 B2
6527737 Kaneshige Mar 2003 B2
6533762 Kanner et al. Mar 2003 B2
6533812 Swanson et al. Mar 2003 B2
6537288 Vargas et al. Mar 2003 B2
6547806 Ding Apr 2003 B1
6551319 Lieberman Apr 2003 B2
6558349 Kirkman May 2003 B1
6569173 Blatter et al. May 2003 B1
6569185 Ungs May 2003 B2
6572629 Kalloo et al. Jun 2003 B2
6578585 Stachowski et al. Jun 2003 B1
6582452 Coleman et al. Jun 2003 B2
6582482 Gillman et al. Jun 2003 B2
6596012 Akerfeldt et al. Jul 2003 B2
6599303 Peterson et al. Jul 2003 B1
6599311 Biggs et al. Jul 2003 B1
6602263 Swanson et al. Aug 2003 B1
6610072 Christy et al. Aug 2003 B1
6613059 Schaller et al. Sep 2003 B2
6613060 Adams et al. Sep 2003 B2
6616686 Coleman et al. Sep 2003 B2
6620165 Wellisz Sep 2003 B2
6623509 Ginn Sep 2003 B2
6623510 Carley et al. Sep 2003 B2
6626918 Ginn et al. Sep 2003 B1
6626919 Swanstrom Sep 2003 B1
6626920 Whayne Sep 2003 B2
6632197 Lyon Oct 2003 B2
6632238 Ginn et al. Oct 2003 B2
6634537 Chen Oct 2003 B2
6645205 Ginn Nov 2003 B2
6645225 Atkinson Nov 2003 B1
6645255 Atkinson Nov 2003 B2
6652538 Kayan et al. Nov 2003 B2
6652556 VanTassel et al. Nov 2003 B1
6663633 Pierson, III Dec 2003 B1
6663655 Ginn et al. Dec 2003 B2
6669714 Coleman et al. Dec 2003 B2
6673083 Kayan et al. Jan 2004 B1
6676671 Robertson et al. Jan 2004 B2
6676685 Pedros et al. Jan 2004 B2
6679904 Gleeson et al. Jan 2004 B2
6685707 Roman et al. Feb 2004 B2
6689147 Koster, Jr. Feb 2004 B1
6695867 Ginn et al. Feb 2004 B2
6699256 Logan et al. Mar 2004 B1
6702826 Liddicoat et al. Mar 2004 B2
6712836 Berg et al. Mar 2004 B1
6712837 Akerfeldt et al. Mar 2004 B2
6719777 Ginn et al. Apr 2004 B2
6726704 Loshakove et al. Apr 2004 B1
6736822 McClellan et al. May 2004 B2
6743195 Zucker Jun 2004 B2
6743243 Roy et al. Jun 2004 B1
6743259 Ginn Jun 2004 B2
6746472 Frazier et al. Jun 2004 B2
6749621 Pantages et al. Jun 2004 B2
6749622 McGuckin et al. Jun 2004 B2
6752813 Goldfarb et al. Jun 2004 B2
6755842 Kanner et al. Jun 2004 B2
6767356 Kanner et al. Jul 2004 B2
6776785 Yencho et al. Aug 2004 B1
6780197 Roe et al. Aug 2004 B2
6786915 Akerfeldt et al. Sep 2004 B2
6790218 Jayaraman Sep 2004 B2
6790220 Morris et al. Sep 2004 B2
6837893 Miller Jan 2005 B2
6837906 Ginn Jan 2005 B2
6846319 Ginn et al. Jan 2005 B2
6849078 Durgin et al. Feb 2005 B2
6860895 Akerfeldt et al. Mar 2005 B1
6890343 Ginn et al. May 2005 B2
6896687 Dakov May 2005 B2
6896692 Ginn et al. May 2005 B2
6904647 Byers, Jr. Jun 2005 B2
6913607 Ainsworth et al. Jul 2005 B2
6926723 Mulhauser et al. Aug 2005 B1
6926731 Coleman et al. Aug 2005 B2
6929634 Dorros et al. Aug 2005 B2
6942641 Seddon Sep 2005 B2
6942674 Belef et al. Sep 2005 B2
6942691 Chuter Sep 2005 B1
6964668 Modesitt et al. Nov 2005 B2
6969397 Ginn Nov 2005 B2
6984238 Gifford, III et al. Jan 2006 B2
6989003 Wing et al. Jan 2006 B2
6989016 Tallarida et al. Jan 2006 B2
7001398 Carley et al. Feb 2006 B2
7001400 Modesitt et al. Feb 2006 B1
7008435 Cummins Mar 2006 B2
7008439 Janzen et al. Mar 2006 B1
7025776 Houser et al. Apr 2006 B1
7033379 Peterson Apr 2006 B2
7060084 Loshakove et al. Jun 2006 B1
7063711 Loshakove et al. Jun 2006 B1
7074232 Kanner et al. Jul 2006 B2
7076305 Imran et al. Jul 2006 B2
7083635 Ginn Aug 2006 B2
7087064 Hyde Aug 2006 B1
7108709 Cummins Sep 2006 B2
7111768 Cummins et al. Sep 2006 B2
7112225 Ginn Sep 2006 B2
7144411 Ginn et al. Dec 2006 B2
7163551 Anthony et al. Jan 2007 B2
7169158 Sniffin et al. Jan 2007 B2
7169164 Borillo et al. Jan 2007 B2
7211101 Carley et al. May 2007 B2
7229452 Kayan Jun 2007 B2
7261716 Strobel et al. Aug 2007 B2
7306614 Weller et al. Dec 2007 B2
7311720 Mueller et al. Dec 2007 B2
7316704 Bagaoisan et al. Jan 2008 B2
7316706 Bloom et al. Jan 2008 B2
7322995 Buckman et al. Jan 2008 B2
7326230 Ravikumar Feb 2008 B2
7331979 Khosravi et al. Feb 2008 B2
7335220 Khosravi et al. Feb 2008 B2
D566272 Walburg et al. Apr 2008 S
7361178 Hearn et al. Apr 2008 B2
7361183 Ginn Apr 2008 B2
7361185 O'Malley et al. Apr 2008 B2
7393363 Ginn Jul 2008 B2
7396359 Derowe et al. Jul 2008 B1
7431727 Cole et al. Oct 2008 B2
7431729 Chanduszko Oct 2008 B2
7465286 Patterson et al. Dec 2008 B2
7533790 Knodel et al. May 2009 B1
7582103 Young et al. Sep 2009 B2
7582104 Corcoran et al. Sep 2009 B2
7597706 Kanner et al. Oct 2009 B2
7618427 Ortiz et al. Nov 2009 B2
7622628 Bergin et al. Nov 2009 B2
7645285 Cosgrove et al. Jan 2010 B2
D611144 Reynolds Mar 2010 S
7678135 Maahs et al. Mar 2010 B2
7727249 Rahmani Jun 2010 B2
7780696 Daniel et al. Aug 2010 B2
7799042 Williamson, IV et al. Sep 2010 B2
7819895 Ginn et al. Oct 2010 B2
7931671 Tenerz Apr 2011 B2
7967842 Bakos Jun 2011 B2
8103327 Harlev et al. Jan 2012 B2
8105352 Egnelöv Jan 2012 B2
8226666 Zarbatany et al. Jul 2012 B2
20010007077 Ginn et al. Jul 2001 A1
20010031972 Robertson et al. Oct 2001 A1
20010031973 Nobles et al. Oct 2001 A1
20010044639 Levinson Nov 2001 A1
20010046518 Sawhney Nov 2001 A1
20010047180 Grudem et al. Nov 2001 A1
20020022822 Cragg et al. Feb 2002 A1
20020026208 Belef Feb 2002 A1
20020026215 Redmond et al. Feb 2002 A1
20020026216 Grimes Feb 2002 A1
20020029050 Gifford, III et al. Mar 2002 A1
20020038127 Blatter et al. Mar 2002 A1
20020042622 Vargas et al. Apr 2002 A1
20020049427 Wiener et al. Apr 2002 A1
20020049472 Coleman et al. Apr 2002 A1
20020058960 Hudson et al. May 2002 A1
20020062104 Ashby et al. May 2002 A1
20020072768 Ginn Jun 2002 A1
20020077657 Ginn et al. Jun 2002 A1
20020082641 Ginn et al. Jun 2002 A1
20020095181 Beyar Jul 2002 A1
20020099389 Michler et al. Jul 2002 A1
20020106409 Sawhney et al. Aug 2002 A1
20020107542 Kanner et al. Aug 2002 A1
20020133193 Ginn et al. Sep 2002 A1
20020151921 Kanner et al. Oct 2002 A1
20020151963 Brown et al. Oct 2002 A1
20020183786 Girton Dec 2002 A1
20020183787 Wahr et al. Dec 2002 A1
20020193808 Belef et al. Dec 2002 A1
20020198562 Ackerfeldt et al. Dec 2002 A1
20020198589 Leong Dec 2002 A1
20030004543 Gleeson et al. Jan 2003 A1
20030009180 Hinchliffe et al. Jan 2003 A1
20030018358 Saadat Jan 2003 A1
20030023248 Parodi Jan 2003 A1
20030032981 Kanner et al. Feb 2003 A1
20030033006 Phillips et al. Feb 2003 A1
20030045893 Ginn Mar 2003 A1
20030055455 Yang et al. Mar 2003 A1
20030060846 Egnelov et al. Mar 2003 A1
20030065358 Frecker et al. Apr 2003 A1
20030078598 Ginn et al. Apr 2003 A1
20030083679 Grudem et al. May 2003 A1
20030093096 McGuckin et al. May 2003 A1
20030093108 Avellanet et al. May 2003 A1
20030097140 Kanner May 2003 A1
20030109890 Kanner et al. Jun 2003 A1
20030125766 Ding Jul 2003 A1
20030139819 Beer et al. Jul 2003 A1
20030144695 McGuckin, Jr. et al. Jul 2003 A1
20030158577 Pantages et al. Aug 2003 A1
20030158578 Pantages et al. Aug 2003 A1
20030195504 Tallarida et al. Oct 2003 A1
20030195561 Carley et al. Oct 2003 A1
20030208211 Kortenbach Nov 2003 A1
20030233095 Urbanski et al. Dec 2003 A1
20040009205 Sawhney Jan 2004 A1
20040009289 Carley et al. Jan 2004 A1
20040010285 Carley et al. Jan 2004 A1
20040039414 Carley et al. Feb 2004 A1
20040044350 Martin et al. Mar 2004 A1
20040049224 Buehlmann et al. Mar 2004 A1
20040059376 Breuniger Mar 2004 A1
20040068273 Fariss et al. Apr 2004 A1
20040073236 Carley et al. Apr 2004 A1
20040073255 Ginn et al. Apr 2004 A1
20040078053 Berg et al. Apr 2004 A1
20040082906 Tallarida et al. Apr 2004 A1
20040087985 Loshakove et al. May 2004 A1
20040092962 Thornton et al. May 2004 A1
20040092964 Modesitt et al. May 2004 A1
20040092968 Caro et al. May 2004 A1
20040092973 Chandusko et al. May 2004 A1
20040093024 Lousararian et al. May 2004 A1
20040093027 Fabisiak et al. May 2004 A1
20040097978 Modesitt et al. May 2004 A1
20040106980 Solovay et al. Jun 2004 A1
20040127940 Ginn et al. Jul 2004 A1
20040143290 Brightbill Jul 2004 A1
20040143291 Corcoran et al. Jul 2004 A1
20040153122 Palermo Aug 2004 A1
20040153123 Palermo et al. Aug 2004 A1
20040158127 Okada Aug 2004 A1
20040158287 Cragg et al. Aug 2004 A1
20040158309 Wachter et al. Aug 2004 A1
20040167511 Buehlmann et al. Aug 2004 A1
20040167570 Pantages Aug 2004 A1
20040191277 Sawhney et al. Sep 2004 A1
20040215232 Belhe et al. Oct 2004 A1
20040243216 Gregorich Dec 2004 A1
20040249412 Snow et al. Dec 2004 A1
20040254591 Kanner et al. Dec 2004 A1
20040267193 Bagaoisan et al. Dec 2004 A1
20040267308 Bagaoisan et al. Dec 2004 A1
20040267312 Kanner et al. Dec 2004 A1
20050038460 Jayaraman Feb 2005 A1
20050038500 Boylan et al. Feb 2005 A1
20050059982 Zung et al. Mar 2005 A1
20050075654 Kelleher Apr 2005 A1
20050075665 Brenzel et al. Apr 2005 A1
20050085851 Fiehler et al. Apr 2005 A1
20050085854 Ginn Apr 2005 A1
20050085855 Forsberg Apr 2005 A1
20050090859 Ravlkumar Apr 2005 A1
20050119695 Carley et al. Jun 2005 A1
20050121042 Belhe et al. Jun 2005 A1
20050149117 Khosravi et al. Jul 2005 A1
20050152949 Hotchkiss et al. Jul 2005 A1
20050154401 Weldon et al. Jul 2005 A1
20050165357 McGuckin et al. Jul 2005 A1
20050169974 Tenerez et al. Aug 2005 A1
20050177189 Ginn et al. Aug 2005 A1
20050187564 Jayaraman Aug 2005 A1
20050203552 Laufer et al. Sep 2005 A1
20050216057 Coleman et al. Sep 2005 A1
20050222614 Ginn et al. Oct 2005 A1
20050228443 Yassinzadeh Oct 2005 A1
20050234508 Cummins et al. Oct 2005 A1
20050245876 Khosravi et al. Nov 2005 A1
20050267528 Ginn et al. Dec 2005 A1
20050267530 Cummins et al. Dec 2005 A1
20050273136 Belef et al. Dec 2005 A1
20050273137 Ginn Dec 2005 A1
20050274768 Cummins et al. Dec 2005 A1
20050283188 Loshakove et al. Dec 2005 A1
20060020270 Jabba et al. Jan 2006 A1
20060030867 Zadno Feb 2006 A1
20060034930 Khosravi et al. Feb 2006 A1
20060047313 Khanna et al. Mar 2006 A1
20060058844 White et al. Mar 2006 A1
20060064115 Allen et al. Mar 2006 A1
20060100664 Pai et al. May 2006 A1
20060135989 Carley et al. Jun 2006 A1
20060142784 Kontos Jun 2006 A1
20060144479 Carley et al. Jul 2006 A1
20060167484 Carley et al. Jul 2006 A1
20060190014 Ginn et al. Aug 2006 A1
20060190036 Wendel et al. Aug 2006 A1
20060190037 Carley et al. Aug 2006 A1
20060190038 Carley et al. Aug 2006 A1
20060195123 Ginn et al. Aug 2006 A1
20060195124 Ginn et al. Aug 2006 A1
20060206146 Tenerez Sep 2006 A1
20060253037 Ginn et al. Nov 2006 A1
20060253072 Pai et al. Nov 2006 A1
20060259049 Harada et al. Nov 2006 A1
20060287674 Ginn et al. Dec 2006 A1
20060293698 Douk Dec 2006 A1
20070005093 Cox Jan 2007 A1
20070010853 Ginn et al. Jan 2007 A1
20070010854 Cummins et al. Jan 2007 A1
20070021778 Carly Jan 2007 A1
20070027476 Harris et al. Feb 2007 A1
20070027525 Ben-Muvhar Feb 2007 A1
20070049967 Sibbitt, Jr. et al. Mar 2007 A1
20070049968 Sibbitt, Jr. et al. Mar 2007 A1
20070049970 Belef et al. Mar 2007 A1
20070060895 Sibbitt, Jr. et al. Mar 2007 A1
20070060950 Khosravi et al. Mar 2007 A1
20070060951 Shannon Mar 2007 A1
20070083230 Javois Apr 2007 A1
20070083231 Lee Apr 2007 A1
20070112304 Voss May 2007 A1
20070112365 Hilal et al. May 2007 A1
20070112385 Conlon May 2007 A1
20070123816 Zhu et al. May 2007 A1
20070123817 Khosravi et al. May 2007 A1
20070123936 Goldin et al. May 2007 A1
20070172430 Brito et al. Jul 2007 A1
20070179527 Eskuri et al. Aug 2007 A1
20070185530 Chin-Chen et al. Aug 2007 A1
20070203506 Sibbitt, Jr. et al. Aug 2007 A1
20070203507 McLaughlin et al. Aug 2007 A1
20070213747 Monassevitch et al. Sep 2007 A1
20070225755 Preinitz et al. Sep 2007 A1
20070225756 Preinitz et al. Sep 2007 A1
20070225757 Preinitz et al. Sep 2007 A1
20070225758 Preinitz et al. Sep 2007 A1
20070239209 Fallman Oct 2007 A1
20070250080 Jones et al. Oct 2007 A1
20070265658 Nelson et al. Nov 2007 A1
20070270904 Ginn Nov 2007 A1
20070275036 Green, III et al. Nov 2007 A1
20070276416 Ginn et al. Nov 2007 A1
20070276488 Wachter et al. Nov 2007 A1
20070282352 Carley et al. Dec 2007 A1
20070282373 Ashby et al. Dec 2007 A1
20080004636 Walberg Jan 2008 A1
20080004640 Ellingwood Jan 2008 A1
20080009794 Bagaoisan et al. Jan 2008 A1
20080033459 Shafi et al. Feb 2008 A1
20080058839 Nobles et al. Mar 2008 A1
20080065151 Ginn Mar 2008 A1
20080086075 Isik et al. Apr 2008 A1
20080093414 Bender et al. Apr 2008 A1
20080114378 Matsushita May 2008 A1
20080114395 Mathisen et al. May 2008 A1
20080177288 Carlson Jul 2008 A1
20080210737 Ginn et al. Sep 2008 A1
20080221616 Ginn et al. Sep 2008 A1
20080243148 Mikkaichi et al. Oct 2008 A1
20080243182 Bates et al. Oct 2008 A1
20080269801 Coleman et al. Oct 2008 A1
20080269802 Coleman et al. Oct 2008 A1
20080272173 Coleman et al. Nov 2008 A1
20080287988 Smith et al. Nov 2008 A1
20080300628 Ellingwood Dec 2008 A1
20080312666 Ellingwood et al. Dec 2008 A1
20080312686 Ellingwood Dec 2008 A1
20080312740 Wachter et al. Dec 2008 A1
20080319475 Clark Dec 2008 A1
20090054912 Heanue et al. Feb 2009 A1
20090105728 Noda et al. Apr 2009 A1
20090112306 Bonsignore et al. Apr 2009 A1
20090137900 Bonner et al. May 2009 A1
20090157101 Reyes et al. Jun 2009 A1
20090157102 Reynolds et al. Jun 2009 A1
20090157103 Walberg et al. Jun 2009 A1
20090171388 Dave et al. Jul 2009 A1
20090177212 Carley et al. Jul 2009 A1
20090177213 Carley et al. Jul 2009 A1
20090187215 Mackiewicz et al. Jul 2009 A1
20090216267 Willard et al. Aug 2009 A1
20090227938 Fasching et al. Sep 2009 A1
20090230168 Coleman et al. Sep 2009 A1
20090254119 Sibbitt, Jr. et al. Oct 2009 A1
20090287244 Kokish Nov 2009 A1
20090312789 Kassab et al. Dec 2009 A1
20100042144 Bennett Feb 2010 A1
20100114156 Mehl May 2010 A1
20100114159 Roorda et al. May 2010 A1
20100130965 Sibbitt, Jr. et al. May 2010 A1
20100168790 Clark Jul 2010 A1
20100179567 Voss et al. Jul 2010 A1
20100179571 Voss Jul 2010 A1
20100179572 Voss et al. Jul 2010 A1
20100179589 Roorda et al. Jul 2010 A1
20100179590 Fortson et al. Jul 2010 A1
20100185234 Fortson et al. Jul 2010 A1
20100249828 Mavani et al. Sep 2010 A1
20110066163 Cho et al. Mar 2011 A1
20110178548 Tenerz Jul 2011 A1
20110270282 Lemke Nov 2011 A1
20120035630 Roorda Feb 2012 A1
20120245603 Voss Sep 2012 A1
20120245623 Karineimi et al. Sep 2012 A1
20120245626 Ellingwood et al. Sep 2012 A1
20120310261 Cummins et al. Dec 2012 A1
20130006274 Walberg et al. Jan 2013 A1
Foreign Referenced Citations (143)
Number Date Country
2003297432 Jul 2004 AU
2 339 060 Feb 2000 CA
197 11 288 Jan 1998 DE
297 23 736 Apr 1999 DE
19859952 Feb 2000 DE
102006056283 Jun 2008 DE
0 386 361 Sep 1990 EP
0 534 696 Mar 1993 EP
0 621 032 Oct 1994 EP
0 756 851 Feb 1997 EP
0 774 237 May 1997 EP
0 858 776 Aug 1998 EP
0 941 697 Sep 1999 EP
1 867 287 Dec 2007 EP
2 443 238 Jul 1980 FR
2 715 290 Jul 1995 FR
2 722 975 Feb 1996 FR
2 768 324 Mar 1999 FR
1 358 466 Jul 1974 GB
2 075 144 Nov 1981 GB
2 397 240 Jul 2004 GB
S 20000722 Oct 2001 IE
S 20000724 Oct 2001 IE
S 20010547 Jul 2002 IE
S 20010815 Jul 2002 IE
S 20010748 Aug 2002 IE
S 20010749 Aug 2002 IE
S 20020452 Dec 2002 IE
S 20020664 Feb 2003 IE
S 20020665 Feb 2003 IE
S 20020451 Jul 2003 IE
S 20020552 Jul 2003 IE
S 20030424 Dec 2003 IE
S 20030490 Jan 2004 IE
S 20040368 Nov 2005 IE
S 20050342 Nov 2005 IE
58-181006 Dec 1983 JP
12 74750 Nov 1989 JP
11500642 Aug 1997 JP
2000102546 Apr 2000 JP
9302140 Jul 1995 NL
171425 Apr 1997 PL
2086192 Aug 1997 RU
495067 Dec 1975 SU
912155 Mar 1982 SU
1243708 Jul 1986 SU
1324650 Jul 1987 SU
1405828 Jun 1988 SU
1456109 Feb 1989 SU
1560133 Apr 1990 SU
WO 9624291 Aug 1996 WO
WO 9707741 Mar 1997 WO
WO 9720505 Jun 1997 WO
WO 9727897 Aug 1997 WO
WO 9806346 Feb 1998 WO
WO 9806448 Feb 1998 WO
WO 9816161 Apr 1998 WO
WO 9817179 Apr 1998 WO
WO 9818389 May 1998 WO
WO 9824374 Jun 1998 WO
WO 9825508 Jun 1998 WO
WO 9858591 Dec 1998 WO
WO 9921491 May 1999 WO
WO 9940849 Aug 1999 WO
WO 9960941 Dec 1999 WO
WO 9962408 Dec 1999 WO
WO 9962415 Dec 1999 WO
WO 0006029 Feb 2000 WO
WO 0007505 Feb 2000 WO
WO 0007640 Feb 2000 WO
WO 0027311 May 2000 WO
WO 0027313 May 2000 WO
WO 0056223 Sep 2000 WO
WO 0056227 Sep 2000 WO
WO 0056228 Sep 2000 WO
WO 0071032 Nov 2000 WO
WO 0121058 Mar 2001 WO
WO 0135832 May 2001 WO
WO 0147594 Jul 2001 WO
WO 0149186 Jul 2001 WO
WO 0191628 Dec 2001 WO
WO 0219915 Mar 2002 WO
WO 0219920 Mar 2002 WO
WO 0219922 Mar 2002 WO
WO 0219924 Mar 2002 WO
WO 0228286 Apr 2002 WO
WO 0238055 May 2002 WO
WO 0245593 Jun 2002 WO
WO 0245594 Jun 2002 WO
WO 02062234 Aug 2002 WO
WO 02098302 Dec 2002 WO
WO 03013363 Feb 2003 WO
WO 03013364 Feb 2003 WO
WO 03047434 Jun 2003 WO
WO 03071955 Sep 2003 WO
WO 03071956 Sep 2003 WO
WO 03071957 Sep 2003 WO
WO 03094748 Nov 2003 WO
WO 03101310 Dec 2003 WO
WO 2004004578 Jan 2004 WO
WO 2004012602 Feb 2004 WO
WO 2004060169 Jul 2004 WO
WO 2004069054 Aug 2004 WO
WO 2005000126 Jan 2005 WO
WO 2005006990 Jan 2005 WO
WO 2005041782 May 2005 WO
WO 2005063129 Jul 2005 WO
WO 2005082256 Sep 2005 WO
WO 2005092204 Oct 2005 WO
WO 2005110240 Nov 2005 WO
WO 2005112782 Dec 2005 WO
WO 2005115251 Dec 2005 WO
WO 2005115521 Dec 2005 WO
WO 2006000514 Jan 2006 WO
WO 2006026116 Mar 2006 WO
WO 2006052611 May 2006 WO
WO 2006052612 May 2006 WO
WO 2006078578 Jul 2006 WO
WO 2006083889 Aug 2006 WO
PCTUS0778051 Sep 2006 WO
WO 2006115901 Nov 2006 WO
WO 2006115904 Nov 2006 WO
WO 2006118877 Nov 2006 WO
WO 2007005585 Jan 2007 WO
WO 2007025014 Mar 2007 WO
WO 2007025017 Mar 2007 WO
WO 2007025018 Mar 2007 WO
WO 2007025019 Mar 2007 WO
WO 2007081836 Jul 2007 WO
WO 2007088069 Aug 2007 WO
WO 2008031102 Mar 2008 WO
WO 2008036384 Mar 2008 WO
WO 2008074027 Jun 2008 WO
WO 2008150915 Dec 2008 WO
WO 2009079091 Jun 2009 WO
WO 2010031050 Mar 2010 WO
WO 2010062693 Jun 2010 WO
WO 2010081101 Jul 2010 WO
WO 2010081102 Jul 2010 WO
WO 2010081103 Jul 2010 WO
WO 2010081106 Jul 2010 WO
20010527 Jan 2001 ZA
200100528 Jan 2001 ZA
Non-Patent Literature Citations (569)
Entry
U.S. Appl. No. 61/015,144, filed Dec. 19, 2007, Mackiewicz et al.
U.S. Appl. No. 61/109,822, filed Oct. 30, 2008, Mehl et al.
U.S. Appl. No. 61/143,748, filed Jan. 9, 2009, Mehl et al.
U.S. Appl. No. 61/143,751, filed Jan. 9, 2009, Voss et al.
U.S. Appl. No. 61/145,468, filed Jan. 16, 2009, Fortson et al.
U.S. Appl. No. 09/610,128, filed Jul. 5, 2000, Kerievsky.
U.S. Appl. No. 09/866,551, filed May 25, 2001, Ginn.
U.S. Appl. No. 12/548,274, filed Aug. 26, 2009, Clark.
U.S. Appl. No. 12/724,304, filed Mar. 15, 2010, Fortson.
U.S. Appl. No. 12/848,642, filed Aug. 2, 2010, Fortson et al.
U.S. Appl. No. 10/006,400, Aug. 2, 2010, Notice of Allowance.
U.S. Appl. No. 10/517,004, Aug. 3, 2010, Notice of Allowance.
U.S. Appl. No. 10/541,083, Aug. 17, 2010, Notice of Allowance.
U.S. Appl. No. 10/638,115, Aug. 13, 2010, Notice of Allowance.
U.S. Appl. No. 10/682,459, Apr. 28, 2010, Office Action.
U.S. Appl. No. 10/787,073, Aug. 25, 2010, Notice of Allowance.
U.S. Appl. No. 11/048,503, Jul. 30, 2010, Notice of Allowance.
U.S. Appl. No. 11/427,309, May 28, 2008, Office Action.
U.S. Appl. No. 11/427,309, Jan. 2, 2009, Office Action.
U.S. Appl. No. 11/427,309, Apr. 20, 2009, Office Action.
U.S. Appl. No. 11/427,309, Nov. 6, 2009, Office Action.
U.S. Appl. No. 11/427,309, Apr. 26, 2010, Office Action.
U.S. Appl. No. 11/508,656, Aug. 30, 2010, Office Action.
U.S. Appl. No. 11/675,462, Aug. 31, 2010, Office Action.
U.S. Appl. No. 11/757,108, Nov. 25, 2009, Office Action.
U.S. Appl. No. 11/958,281, Sep. 2, 2010, Office Action.
U.S. Appl. No. 11/959,334, Jul. 23, 2010, Notice of Allowance.
U.S. Appl. No. 12/403,256, Aug. 19, 2010, Notice of Allowance.
U.S. Appl. No. 10/616,832, Sep. 20, 2010, Notice of Allowance.
U.S. Appl. No. 10/787,073, Sep. 15, 2010, Issue Notification.
U.S. Appl. No. 11/152,562, Sep. 16, 2010, Notice of Allowance.
U.S. Appl. No. 11/427,297, Sep. 15, 2010, Office Action.
U.S. Appl. No. 11/767,818, Sep. 30, 2010, Office Action.
U.S. Appl. No. 12/365,397, Sep. 13, 2010, Office Action.
U.S. Appl. No. 60/693,531, filed Jun. 24, 2005, Carly.
U.S. Appl. No. 60/696,069, filed Jul. 1, 2005, Pantages et al.
U.S. Appl. No. 60/711,279, filed Aug. 24, 2005, Sibbitt, Jr. et al.
U.S. Appl. No. 60/726,985, filed Oct. 14, 2005, Sibbitt, Jr. et al.
U.S. Appl. No. 60/793,444, filed Apr. 20, 2006, Jones et al.
U.S. Appl. No. 60/946,026, filed Jun. 25, 2007, Ellingwood.
U.S. Appl. No. 60/946,030, filed Jun. 25, 2007, Voss et al.
U.S. Appl. No. 60/946,042, filed Jun. 25, 2007, Ellingwood et al.
U.S. Appl. No. 61/097,072, filed Sep. 15, 2008, Sibbitt, Jr. et al.
U.S. Appl. No. 61/139,995, filed Dec. 22, 2008, Clark.
U.S. Appl. No. 61/141,597, filed Dec. 30, 2008, Clark.
U.S. Appl. No. 12/113,092, filed Apr. 30, 2008, Ginn et al.
U.S. Appl. No. 12/393,877, filed Feb. 26, 2009, Ellingwood et al.
U.S. Appl. No. 12/481,377, filed Jun. 9, 2009, Clark.
Deepak Mital et al, Renal Transplantation Without Sutures Using the Vascular Clipping System for Renal Artery and Vein Anastomosis—A New Technique, Transplantation Issue, Oct. 1996, pp. 1171-1173, vol. 62—No. 8, Section of Transplantation Surgery, Department of General Surgery, Rush-Presbyterian/St. Luke's Medical Center, Chigago, IL.
DL Wessel et al, Outpatient closure of the patent ductus arteriosus, Circulation, May 1988, pp. 1068-1071, vol. 77—No. 5, Department of Anesthesia, Children's Hospital, Boston, MA.
E Pikoulis et al, Arterial reconstruction with vascular clips is safe and quicker than sutured repair, Cardiovascular Surgery, Dec. 1998, pp. 573-578(6), vol. 6—No. 6, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD.
G Gershony et al, Novel vascular sealing device for closure of percutaneous vascular access sites, Cathet. Cardiovasc. Diagn., Jan. 1998, pp. 82-88, vol. 45.
H De Swart et al, A new hemostatic puncture closure device for the immediate sealing of arterial puncture sites, American journal of cardiology, Aug. 1993, pp. 445-449, vol. 72—No. 5, Department of Cardiology, Academic Hospital Maastricht, The Netherlands.
Harrith M. Hasson M.D. , Laparoscopic Cannula Cone with Means for Cannula Stabilization and Wound Closure, The Journal of the American Association of Gynecologic Laparoscopists, May 1998, pp. 183-185, vol. 5—No. 2, Division of Obstetrics and Gynecology, University of Chicago, Chigago, IL.
J. Findlay et al, Carotid Arteriotomy Closure Using a Vascular Clip System, Neurosurgery, Mar. 1998, pp. 550-554, vol. 42—No. 3, Division of Neurosurgery, University of Alberta, Edmonton, Canada.
Jeremy L Gilbert Phd, Wound Closure Biomaterials and Devices, Shock., Mar. 1999, p. 226, vol. 11—No. 3, Institution Northwestern University (editorial review).
Jochen T. Cremer, MD, et al, Different approaches for minimally invasive closure of atrial septal defects, Ann. Thorac. Surg., Nov. 1998, pp. 1648-1652, vol. 67, a Division of Thoracic and Cardiovascular Surgery, Surgical Center, Hannover Medical School. Hannover, Germany.
K Narayanan et al, Simultaneous primary closure of four fasciotomy wounds in a single setting using the Sure-Closure device, Injury, Jul. 1996, pp. 449-451, vol. 27—No. 6, Department of Surgery, Mercy Hospital of Pittsburgh, PA.
Marshall A.C., Lock J.E., Structural and Compliant Anatomy of the Patent Foramen Ovale in Patients Undergoing Transcatheter Closure, Am Heart J Aug. 2000; 140(2); pp. 303-307.
MD Gonze et al, Complications associated with percutaneous closure devices, Conference: Annual Meeting of the Society for Clinical Vascular Surgery, The American journal of surgery, Mar. 1999, pp. 209-211, vol. 178, No. 3, Department of Surgery, Section of Vascular Surgery, Ochsner Medical Institutions, New Orleans, LA.
MD Hellinger et al, Effective peritoneal and fascial closure of abdominal trocar sites utilizing the Endo-Judge, J Laparoendosc Surg., Oct. 1996, pp. 329-332, vol. 6—No. 5, Orlando Regional Medical Center, FL.
Michael Gianturco, A Play on Catheterization, Forbes, Dec. 1996, p. 146, vol. 158—No. 15.
Om Elashry et al, Comparative clinical study of port-closure techniques following laparoscopic surgery, Department of Surgery, Mallickrodt Institute of Radiography, J Am Coll Surg., Oct. 1996, pp. 335-344, vol. 183—No. 4.
P M N Werker, et al, Review of facilitated approaches to vascular anastomosis surgery, Conference: Utrecht MICABG Workshop 2, The Annals of thoracic surgery, Apr. 1996, pp. S122-S127, vol. 63—No. 6, Department of Plastic, Reconstructive and Hand surgery, University Hospital Utrecht Netherlands Departments of Cardiology and Cardiopulmonary Surgery, Heart Lung Institute, Utrecht Netherlands.; Utrect University Hospital Utrecht Netherlands.
Peter Rhee MD et al, Use of Titanium Vascular Staples in Trauma, Journal of Trauma-Injury Infection & Critical Care, Dec. 1998, pp. 1097-1099, vol. 45—No. 6, Institution from the Department of Surgery, Washington Hospital Center, Washington DC, and Uniformed Services University of the Health Sciences, Bethesda, Maryland.
ProstarXL—Percutaneous Vascular Surgical Device, www.Archive.org, Jun. 1998, Original Publisher: http://prostar.com, may also be found at http://web.archive.org/web/19980630040429/www.perclose.com/html/prstrxl.html.
SA Beyer-Enke et al, Immediate sealing of arterial puncture site following femoropopliteal angioplasty: A prospective randomized trial, Cardiovascular and Interventional Radiology 1996, Nov.-Dec. 1996, pp. 406-410, vol. 19—No. 6, Gen Hosp North, Dept Dianost & Intervent Radiol, Nurnberg, Germany (Reprint).
Scott Hensley, Closing Wounds. New Devices seal arterial punctures in double time, Modern Healthcare (United States), Mar. 23, 2008, p. 48.
Sigmund Silber et al, A novel vascular device for closure of percutaneous arterial access sites, The American Journal of Cardiology, Apr. 1999, pp. 1248-1252, vol. 83—No. 8.
Simonetta Blengino et al, A Randomized Study of the 8 French Hemostatic Puncture Closure Device vs Manual Compression After Coronary Interventions, Journal of the American College of Cardiology, Feb. 1995, p. 262A, vol. 25.—No. 2, Supplement 1.
Stretch Comb by Scunci, retrieved via internet at www.scunci.com/productdetail by examiner on Oct. 9, 2007, publication date unavailable.
Sy Nakada et al, Comparison of newer laparoscopic port closure techniques in the porcine model, J Endourol, Oct. 1995, pp. 397-401, vol. 9—No. 5, Department of Surgery/Urology, University of Wisconsin Medical School, Madison.
Taber's Cyclopedic Medical Dictionary, 18th Ed. 1997, pp. 747 and 1420.
Thomas P. Baum RPA-C et al, Delayed Primary Closure Using Silastic Vessel Loops and Skin Staples: Description of the Technique and Case Reports, Annals of Plastic Surgery, Mar. 1999, pp. 337-340, vol. 42—No. 3, Institution Department of Plastic and Reconstructive Surgery, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.
Tomoaki Hinohara, Percutaneous vascular surgery (Prostar® Plus and Techstar® for femoral artery site closure), Interventional Cardiology Newsletter, May-Jul. 1997, pp. 19-28, vol. 5—No. 3-4.
Ut Aker et al, Immediate arterial hemostasis after cardiac catheterization: initial experience with a new puncture closure device, Cathet Cardiovasc Diagn, Mar. 1994, pp. 228-232, vol. 33—No. 3, Missouri Baptist Medical Center, St. Louis.
Wei Qu et al, An absorbable pinned-ring device for microvascular anastomosis of vein grafts: Experimental studies, Microsurgery 1999, Mar. 1999, pp. 128-134, vol. 19—No. 3, Department of Orthopaedic Surgery, Hiroshima University School of Medicine, Hiroshima, Japan.
William G. Kussmaul III MD, et al., Rapid arterial hemostasis and decreased access site complications after cardiac catheterization and angioplasty: Results of a randomized trial of a novel hemostatic device, Journal of the American College of Cardiology, Jun. 1995, pp. 1685-1692, vol. 25—No. 7.
U.S. Appl. No. 09/680,837, Jul. 9, 2002, Office Action.
U.S. Appl. No. 09/680,837, Nov. 6, 2002, Office Action.
U.S. Appl. No. 09/680,837, Mar. 25, 2003, Office Action.
U.S. Appl. No. 09/680,837, Jun. 16, 2003, Notice of Allowance.
U.S. Appl. No. 09/732,178, Aug. 1, 2002, Office Action.
U.S. Appl. No. 09/732,178, Dec. 24, 2002, Office Action.
U.S. Appl. No. 09/732,178, Jun. 10, 2003, Office action.
U.S. Appl. No. 09/732,178, Jul. 3, 2003, Office Action.
U.S. Appl. No. 09/732,178, Nov. 17, 2003, Notice of Allowance.
U.S. Appl. No. 09/732,835, Sep. 11, 2003, Office Action.
U.S. Appl. No. 09/732,835, Feb. 9, 2004, Office Action.
U.S. Appl. No. 09/732,835, Mar. 17, 2004, Notice of Allowance.
U.S. Appl. No. 09/764,813, Mar. 26, 2001 Office Action.
U.S. Appl. No. 09/764,813, Jun. 4, 2001, Notice of Allowance.
U.S. Appl. No. 09/933,299, Feb. 26, 2003, Office Action.
U.S. Appl. No. 09/933,299, Jun. 16, 2003, Notice of Allowance.
U.S. Appl. No. 09/948,813, Jan. 31, 2003, Notice of Allowance.
U.S. Appl. No. 09/949,398, Mar. 4, 2003, Office Action.
U.S. Appl. No. 09/949,398, Jul. 28, 2003, Notice of Allowance.
U.S. Appl. No. 09/949,438, Dec. 17, 2002, Office Action.
U.S. Appl. No. 09/949,438, Apr. 21, 2003, Notice of Allowance.
U.S. Appl. No. 10/006,400, Aug. 27, 2004, Office Action.
U.S. Appl. No. 10/006,400, Feb. 23, 2005, Office Action.
U.S. Appl. No. 10/006,400, Apr. 11, 2005, Office Action.
U.S. Appl. No. 10/006,400, Jul. 27, 2005, Office Action.
U.S. Appl. No. 10/006,400, Mar. 6, 2006, Office Action.
U.S. Appl. No. 10/006,400, May 24, 2006, Office Action.
U.S. Appl. No. 10/006,400, Oct. 26, 2006, Office Action.
U.S. Appl. No. 10/006,400, Apr. 19, 2007, Office Action.
U.S. Appl. No. 10/006,400, Apr. 2, 2008, Office Action.
U.S. Appl. No. 10/006,400, Jan. 2, 2009, Office Action.
U.S. Appl. No. 10/006,400, Jul. 9, 2009, Notice of Allowance.
U.S. Appl. No. 10/006,400, Jan. 13, 2010, Notice of Allowance.
U.S. Appl. No. 10/006,400, Apr. 27, 2010, Notice of Allowance.
U.S. Appl. No. 10/081,717, Sep. 29, 2003, Notice of Allowance.
U.S. Appl. No. 10/081,723, Sep. 29, 2004, Office Action.
U.S. Appl. No. 10/081,723, May 13, 2005, Notice of Allowance.
U.S. Appl. No. 10/081,725, Feb. 9, 2004, Notice of Allowance.
U.S. Appl. No. 10/081,725, Apr. 13, 2004, Office Action.
U.S. Appl. No. 10/081,726, Apr. 11, 2003, Notice of Allowance.
U.S. Appl. No. 10/081,726, Jun. 9, 2003, Notice of Allowance.
U.S. Appl. No. 10/147,774, Nov. 4, 2004, Office Action.
U.S. Appl. No. 10/147,774, May 4, 2005, Office Action.
U.S. Appl. No. 10/147,774, Oct. 18, 2005, Office Action.
U.S. Appl. No. 10/147,774, Apr. 18, 2007, Notice of Allowance.
U.S. Appl. No. 10/147,774, Sep. 27, 2007, Notice of Allowance.
U.S. Appl. No. 10/147,774, Feb. 4, 2008, Notice of Allowance.
U.S. Appl. No. 10/147,774, Jun. 30, 2008, Office Action.
U.S. Appl. No. 10/147,774, Mar. 18, 2009, Office Action.
U.S. Appl. No. 10/147,774, Oct. 26, 2009, Office Action.
U.S. Appl. No. 10/147,774, Jun. 8, 2010, Office Action.
U.S. Appl. No. 10/240,183, Jul. 27, 2004, Office Action.
U.S. Appl. No. 10/240,183, Dec. 17, 2004, Office Action.
U.S. Appl. No. 10/240,183, Mar. 9, 2005, Notice of Allowance.
U.S. Appl. No. 10/240,183, Aug. 11, 2006, Office Action.
U.S. Appl. No. 10/264,306, Feb. 9, 2005, Office Action.
U.S. Appl. No. 10/264,306, Oct. 4, 2005, Office Action.
U.S. Appl. No. 10/264,306, May 10, 2006, Notice of Allowance.
U.S. Appl. No. 10/264,306, Jul. 2, 2007, Notice of Allowance.
U.S. Appl. No. 10/264,306, Feb. 4, 2008, Notice of Allowance.
U.S. Appl. No. 10/264,306, Jun. 27, 2008, Office Action.
U.S. Appl. No. 10/264,306, Feb. 26, 2009, Office Action.
U.S. Appl. No. 10/264,306, Aug. 13, 2009, Office Action.
U.S. Appl. No. 10/264,306, Jan. 27, 2010, Office Action.
U.S. Appl. No. 10/264,306, Jun. 15, 2010, Office Action.
U.S. Appl. No. 10/335,075, Aug. 10, 2005, Office Action.
U.S. Appl. No. 10/335,075, Dec. 19, 2005, Office Action.
U.S. Appl. No. 10/335,075, Apr. 21, 2006, Office Action.
U.S. Appl. No. 10/335,075, Dec. 27, 2006, Notice of Allowance.
U.S. Appl. No. 10/356,214, Nov. 30, 2005, Office Action.
U.S. Appl. No. 10/356,214, Aug. 23, 2006, Office Action.
U.S. Appl. No. 10/356,214, Feb. 13, 2007, Office Action.
U.S. Appl. No. 10/356,214, Sep. 12, 2007, Office Action.
U.S. Appl. No. 10/356,214, Mar. 6, 2008, Office Action.
U.S. Appl. No. 10/356,214, Nov. 4, 2008, Office Action.
U.S. Appl. No. 10/356,214, Apr. 29, 2009, Office Action.
U.S. Appl. No. 10/356,214, Jan. 13, 2010, Notice of Allowance.
U.S. Appl. No. 10/356,214, May 13, 2010, Notice of Allowance.
U.S. Appl. No. 10/435,104, Jun. 10, 2004, Office Action.
U.S. Appl. No. 10/435,104, Sep. 21, 2004, Notice of Allowance.
U.S. Appl. No. 10/435,104, Jan. 3, 2006, Office Action.
U.S. Appl. No. 10/435,104, May 16, 2006, Office Action.
U.S. Appl. No. 10/435,104, Dec. 28, 2006, Notice of Allowance.
U.S. Appl. No. 10/435,104, Jul. 10, 2007, Notice of Allowance.
U.S. Appl. No. 10/435,104, Aug. 2, 2007, Notice of Allowance.
U.S. Appl. No. 10/435,104, Oct. 26, 2007, Notice of Allowance.
U.S. Appl. No. 10/435,104, Nov. 14, 2007, Notice of Allowance.
U.S. Appl. No. 10/435,104, Apr. 4, 2008, Notice of Allowance.
U.S. Appl. No. 10/435,104, Sep. 26, 2008, Notice of Allowance.
U.S. Appl. No. 10/435,104, Dec. 22, 2008, Notice of Allowance.
U.S. Appl. No. 10/435,104, Jul. 23, 2009, Notice of Allowance.
U.S. Appl. No. 10/435,104, Jan. 20, 2010, Notice of Allowance.
U.S. Appl. No. 10/435,104, Jun. 2, 2010, Office Action.
U.S. Appl. No. 10/455,768, Nov. 16, 2004, Office Action.
U.S. Appl. No. 10/455,768, Apr. 6, 2005, Notice of Allowance.
U.S. Appl. No. 10/486,067, Jan. 10, 2006, Office Action.
U.S. Appl. No. 10/486,067, Sep. 20, 2006, Notice of Allowance.
U.S. Appl. No. 10/486,070, Apr. 20, 2005, Office Action.
U.S. Appl. No. 10/486,070, Aug. 10, 2005, Office Action.
U.S. Appl. No. 10/486,070, Oct. 18, 2005, Notice of Allowance.
U.S. Appl. No. 10/517,004, Aug. 13, 2007, Office Action.
U.S. Appl. No. 10/517,004, Jan. 30, 2008, Office Action.
U.S. Appl. No. 10/517,004, Aug. 13, 2008, Notice of Allowance.
U.S. Appl. No. 10/517,004, Feb. 10, 2009, Notice of Allowance.
U.S. Appl. No. 10/517,004, Mar. 24, 2009, Notice of Allowance.
U.S. Appl. No. 10/517,004, Jun. 26, 2009, Notice of Allowance.
U.S. Appl. No. 10/517,004, Jan. 11, 2010, Notice of Allowance.
U.S. Appl. No. 10/517,004, Apr. 23, 2010, Notice of Allowance.
U.S. Appl. No. 10/519,778, Feb. 23, 2006, Office Action.
U.S. Appl. No. 10/519,778, May 31, 2006, Notice of Allowance.
U.S. Appl. No. 10/541,083, Oct. 16, 2007, Office Action.
U.S. Appl. No. 10/541,083, Oct. 31, 2007, Office Action.
U.S. Appl. No. 10/541,083, May 5, 2008, Office Action.
U.S. Appl. No. 10/541,083, Sep. 19, 2008, Notice of Allowance.
U.S. Appl. No. 10/541,083, Dec. 29, 2008, Notice of Allowance.
U.S. Appl. No. 10/541,083, Apr. 16, 2009, Notice of Allowance.
U.S. Appl. No. 10/541,083, Sep. 30, 2009, Notice of Allowance.
U.S. Appl. No. 10/541,083, Feb. 5, 2010, Notice of Allowance.
U.S. Appl. No. 10/541,083, May 10, 2010, Notice of Allowance.
U.S. Appl. No. 10/616,832, Jun. 30, 2006, Office Action.
U.S. Appl. No. 10/616,832, Oct. 20, 2006, Office Action.
U.S. Appl. No. 10/616,832, May 29, 2007, Office Action.
U.S. Appl. No. 10/616,832, Jan. 22, 2008, Office Action.
U.S. Appl. No. 10/616,832, Sep. 17, 2008, Office Action.
U.S. Appl. No. 10/616,832, Jul. 21, 2009, Office Action.
U.S. Appl. No. 10/616,832, Jan. 11, 2010, Notice of Allowance.
U.S. Appl. No. 10/616,832, May 12, 2010, Notice of Allowance.
U.S. Appl. No. 10/617,090, Mar. 22, 2005, Office Action.
U.S. Appl. No. 10/617,090, Jul. 6, 2005, Notice of Allowance.
U.S. Appl. No. 10/617,090, Oct. 5, 2005, Notice of Allowance.
U.S. Appl. No. 10/638,115, Sep. 22, 2006, Office Action.
U.S. Appl. No. 10/638,115, Jan. 31, 2007, Office Action.
U.S. Appl. No. 10/638,115, Sep. 18, 2007, Office Action.
U.S. Appl. No. 10/638,115, Feb. 7, 2008, Office Action.
U.S. Appl. No. 10/638,115, Oct. 29, 2008, Office Action.
U.S. Appl. No. 10/638,115, May 7, 2009, Notice of Allowance.
U.S. Appl. No. 10/638,115, Dec. 1, 2009, Notice of Allowance.
U.S. Appl. No. 10/638,115, Apr. 2, 2010, Notice of Allowance.
U.S. Appl. No. 10/667,144, Sep. 19, 2006, Office Action.
U.S. Appl. No. 10/667,144, May 2, 2007, Office Action.
U.S. Appl. No. 10/667,144, Nov. 19, 2007, Office Action.
U.S. Appl. No. 10/667,144, Dec. 5, 2007, Office Action.
U.S. Appl. No. 10/667,144, May 12, 2008, Office Action.
U.S. Appl. No. 10/667,144, Mar. 24, 2009, Office Action.
U.S. Appl. No. 10/667,144, Nov. 23, 2009, Office Action.
U.S. Appl. No. 10/667,144, Jun. 22, 2010, Office Action.
U.S. Appl. No. 10/669,313, Oct. 31, 2005, Office Action.
U.S. Appl. No. 10/669,313, Jan. 11, 2006, Notice of Allowance.
U.S. Appl. No. 10/669,313, Jun. 28, 2006, Notice of Allowance.
U.S. Appl. No. 10/682,459, Apr. 2, 2008, Office Action.
U.S. Appl. No. 10/682,459, Dec. 4, 2008, Office Action.
U.S. Appl. No. 10/682,459, Jun. 10, 2009, Office Action.
U.S. Appl. No. 10/682,459, Dec. 23, 2009, Office Action.
U.S. Appl. No. 10/786,444, Apr. 24, 2008, Office Action.
U.S. Appl. No. 10/786,444, Oct. 17, 2008, Office Action.
U.S. Appl. No. 10/786,444, Jun. 18, 2009, Office Action.
U.S. Appl. No. 10/786,444, Jan. 14, 2010, Office Action.
U.S. Appl. No. 10/787,073, Feb. 22, 2008, Office Action.
U.S. Appl. No. 10/787,073, Nov. 12, 2008, Office Action.
U.S. Appl. No. 10/787,073, Aug. 13, 2009, Office Action.
U.S. Appl. No. 10/787,073, Feb. 17, 2010, Notice of Allowance.
U.S. Appl. No. 10/908,721, Nov. 25, 2008, Office Action.
U.S. Appl. No. 10/908,721, Jun. 23, 2009, Office Action.
U.S. Appl. No. 10/908,721, Feb. 2, 2010, Office Action.
U.S. Appl. No. 11/048,503, Mar. 13, 2009, Office Action.
U.S. Appl. No. 11/048,503, Jun. 26, 2009, Office Action.
U.S. Appl. No. 11/048,503, Jan. 11, 2010, Notice of Allowance.
U.S. Appl. No. 11/048,503, Apr. 26, 2010, Notice of Allowance.
U.S. Appl. No. 11/113,549, Apr. 16, 2008, Office Action.
U.S. Appl. No. 11/113,549, Jul. 21, 2009, Office Action.
U.S. Appl. No. 11/113,549, Jul. 6, 2010, Office Action.
U.S. Appl. No. 11/152,562, May 13, 2008, Office Action.
U.S. Appl. No. 11/152,562, Feb. 13, 2009, Office Action.
U.S. Appl. No. 11/152,562, Jul. 6, 2009, Office Action.
U.S. Appl. No. 11/152,562, Mar. 31, 2010, Office Action.
U.S. Appl. No. 11/198,811, Aug. 26, 2008, Office Action.
U.S. Appl. No. 11/198,811, Apr. 6, 2009, Office Action.
U.S. Appl. No. 11/198,811, Sep. 22, 2009, Office Action.
U.S. Appl. No. 11/198,811, Jun. 29, 2010, Notice of Allowance.
U.S. Appl. No. 11/316,775, Apr. 16, 2008, Office Action.
U.S. Appl. No. 11/316,775, Aug. 6, 2008, Office Action.
U.S. Appl. No. 11/344,793, Jan. 22, 2009, Office Action.
U.S. Appl. No. 11/344,868, Mar. 25, 2009, Office Action.
U.S. Appl. No. 11/344,891, Apr. 29, 2008, Office Action.
U.S. Appl. No. 11/344,891, Dec. 8, 2008, Office Action.
U.S. Appl. No. 11/344,891, Feb. 26, 2009, Office Action.
U.S. Appl. No. 11/344,891, Oct. 7, 2009, Office Action.
U.S. Appl. No. 11/344,891, May 7, 2010, Office Action.
U.S. Appl. No. 11/390,586, Jun. 24, 2009, Office Action.
U.S. Appl. No. 11/390,586, Jul. 6, 2010, Office Action.
U.S. Appl. No. 11/396,141, May 22, 2009, Office Action.
U.S. Appl. No. 11/396,141, Aug. 26, 2009, Office Action.
U.S. Appl. No. 11/396,141, May 4, 2010, Office Action.
U.S. Appl. No. 11/396,731, Feb. 13, 2009, Office Action.
U.S. Appl. No. 11/396,731, May 22, 2009, Office Action.
U.S. Appl. No. 11/396,731, Jun. 29, 2010, Office Action.
U.S. Appl. No. 11/406,203, May 23, 2008, Notice of Allowance.
U.S. Appl. No. 11/406,203, Sep. 22, 2008, Notice of Allowance.
U.S. Appl. No. 11/406,203, Mar. 3, 2009, Office Action.
U.S. Appl. No. 11/406,203, Sep. 16, 2009, Office Action.
U.S. Appl. No. 11/406,203, Jun. 18, 2010, Notice of Allowance.
U.S. Appl. No. 11/411,925, Feb. 5, 2008, Office Action.
U.S. Appl. No. 11/411,925, Jan. 12, 2009, Office Action.
U.S. Appl. No. 11/411,925, Sep. 10, 2009, Office Action.
U.S. Appl. No. 11/427,297, Jan. 30, 2009, Office Action.
U.S. Appl. No. 11/427,297, Sep. 15, 2009, Office Action.
U.S. Appl. No. 11/455,993, Feb. 17, 2009, Office Action.
U.S. Appl. No. 11/455,993, Dec. 16, 2009, Office Action.
U.S. Appl. No. 11/508,656, Dec. 9, 2009, Office Action.
U.S. Appl. No. 11/508,656, Mar. 25, 2010, Office Action.
U.S. Appl. No. 11/508,662, Dec. 28, 2009, Office Action.
U.S. Appl. No. 11/508,662, Apr. 14, 2010, Office Action.
U.S. Appl. No. 11/508,715, Jan. 6, 2010, Office Action.
U.S. Appl. No. 11/508,715, Apr. 26, 2010, Office Action.
U.S. Appl. No. 11/532,325, Feb. 23, 2009, Office Action.
U.S. Appl. No. 11/532,325, Jun. 17, 2009, Office Action.
U.S. Appl. No. 11/532,325, Jan. 5, 2010, Office Action.
U.S. Appl. No. 11/532,576, Mar. 1, 2010, Office Action.
U.S. Appl. No. 11/532,576, Apr. 23, 2010, Office Action.
U.S. Appl. No. 11/674,930, Jan. 8, 2009, Office Action.
U.S. Appl. No. 11/674,930, Jun. 4, 2009, Office Action.
U.S. Appl. No. 11/674,930, Jan. 8, 2010, Office Action.
U.S. Appl. No. 11/675,462, Dec. 10, 2009, Office Action.
U.S. Appl. No. 11/744,089, Nov. 26, 2008, Office Action.
U.S. Appl. No. 11/744,089, Aug. 14, 2009, Office Action.
U.S. Appl. No. 11/767,818, Dec. 24, 2009, Office Action.
U.S. Appl. No. 11/767,818, Mar. 22, 2010, Office Action.
U.S. Appl. No. 11/958,295, Aug. 27, 2009, Office Action.
U.S. Appl. No. 11/958,295, May 25, 2010, Office Action.
U.S. Appl. No. 11/959,334, Aug. 19, 2009, Office Action.
U.S. Appl. No. 11/959,334, Jan. 12, 2010, Notice of Allowance.
U.S. Appl. No. 11/959,334, Apr. 14, 2010, Notice of Allowance.
U.S. Appl. No. 12/106,928, Jan. 23, 2009, Office Action.
U.S. Appl. No. 12/106,928, Oct. 5, 2009, Office Action.
U.S. Appl. No. 12/106,928, May 10, 2010, Office Action.
U.S. Appl. No. 12/106,937, Mar. 30, 2009, Office Action.
U.S. Appl. No. 12/106,937, Nov. 18, 2009, Office Action.
U.S. Appl. No. 12/113,851, Apr. 27, 2010, Office Action.
U.S. Appl. No. 12/113,851, Jun. 24, 2010, Office Action.
U.S. Appl. No. 12/402,398, Mar. 9, 2010, Office Action.
U.S. Appl. No. 12/402,398, May 20, 2010, Office Action.
U.S. Appl. No. 12/403,256, Dec. 16, 2009, Office Action.
U.S. Appl. No. 12/403,256, Mar. 30, 2010, Office Action.
U.S. Appl. No. 12/403,277, Jul. 8, 2010, Office Action.
U.S. Appl. No. 29/296,370, Aug. 18, 2008, Office Action.
U.S. Appl. No. 29/296,370, Dec. 2, 2008, Notice of Allowance.
U.S. Appl. No. 29/296,370, Apr. 1, 2009, Notice of Allowance.
U.S. Appl. No. 29/296,370, Feb. 10, 2010, Issue Notification.
U.S. Appl. No. 09/866,551, filed May 25, 2001.
U.S. Appl. No. 11/396,141, filed Mar. 31. 2006.
U.S. Appl. No. 11,675,462, filed Feb. 15, 2007.
U.S. Appl. No. 11/744,089, filed May 3, 2007.
Database WPI; Section PQ, Week 200120; Derwent Publications Ltd., London GB; AN 2001-203165; XP002199926 & ZA 200 100 528 A (Anthony T), Feb. 28, 2001 abstract.
“Hand tool for forming telephone connections—comprises pliers with reciprocably driven ram crimping clip around conductors against anvil”, Derwant-ACC—No. 1978-B8090A.
U.S. Appl. No. 10/356,214, Sep. 3, 2010, Notice of Allowance.
U.S. Appl. No. 10/435,104, Oct. 5, 2010, Notice of Allowance.
U.S. Appl. No. 10/682,459, Oct. 12, 2010, Office Action.
U.S. Appl. No. 11/406,203, Oct. 6, 2010, Issue Notification.
U.S. Appl. No. 11/532,576, Oct. 13, 2010, Notice of Allowance.
U.S. Appl. No. 11/958,281, Oct. 8, 2010, Office Action.
U.S. Appl. No. 12/114,031, Oct. 5, 2010, Office Action.
U.S. Appl. No. 12/403,277, Oct. 12, 2010, Office Action.
U.S. Appl. No. 11/508,715, Oct. 18, 2010, Office Action.
U.S. Appl. No. 10/616,832, Jan. 26, 2011, Issue Notification.
U.S. Appl. No. 11/152,562, Jan. 26, 2011, Issue Notification.
U.S. Appl. No. 12/897,358, filed Oct. 4, 2010, Carley.
U.S. Appl. No. 12/941,809, filed Nov. 8, 2010, Ginn et al.
U.S. Appl. No. 12/950,628, filed Nov. 19, 2010, Walberg et al.
U.S. Appl. No. 12/955,859, filed Nov. 29, 2010, Ginn.
U.S. Appl. No. 12/961,331, filed Dec. 6, 2010, Voss.
U.S. Appl. No. 12/945,646, filed Nov. 12, 2010, Carley et al.
U.S. Appl. No. 12/966,923, filed Dec. 13, 2010, Cummins et al.
U.S. Appl. No. 12/973,204, filed Dec. 20, 2010, Jabba et al.
U.S. Appl. No. 12/987,792, filed Jan. 10, 2011, Palermo et al.
U.S. Appl. No. 10/147,774, Dec. 2, 2010, Notice of Allowance.
U.S. Appl. No. 10/435,104, Jan. 12, 2011, Issue Notification.
U.S. Appl. No. 10/517,004, Nov. 23, 2010, Issue Notification.
U.S. Appl. No. 10/541,083, Dec. 1, 2010, Issue Notification.
U.S. Appl. No. 10/638,115, Dec. 22, 2010, Issue Notification.
U.S. Appl. No. 11/048,503, Dec. 8, 2010, Issue Notification.
U.S. Appl. No. 11/113,549, Jan. 4, 2011, Office Action.
U.S. Appl. No. 11/198,811, Oct. 20, 2010, Issue Notification.
U.S. Appl. No. 11/427,309, Nov. 15, 2010, Office Action.
U.S. Appl. No. 11/959,334, Nov. 10, 2010, Issue Notification.
U.S. Appl. No. 12/106,928, Oct. 25, 2010, Office Action.
U.S. Appl. No. 12/113,851, Dec. 16, 2010, Office Action.
U.S. Appl. No. 12/114,031, Nov. 22, 2010, Office Action.
U.S. Appl. No. 12/114,091, Oct. 27, 2010, Office Action.
U.S. Appl. No. 12/114,091, Dec. 17, 2010, Office Action.
U.S. Appl. No. 12/402,398, Jan. 24, 2011, Office Action.
U.S. Appl. No. 12/403,256, Nov. 23, 2010, Issue Notification.
U.S. Appl. No. 12/945,646, Jan. 20, 2011, Office Action.
U.S. Appl. No. 11/344,891, Jan. 22, 2013, Notice of Allowance.
U.S. Appl. No. 12/961,331, Feb. 1, 2013, Office Action.
U.S. Appl. No. 13/030,922, Jan. 31, 2013, Office Action.
U.S. Appl. No. 13/153,594, Jan. 29, 2013, Office Action.
U.S. Appl. No. 13/615,547, Jan. 18, 2013, Office Action.
U.S. Appl. No. 11/767,818, Feb. 3, 2012, Notice of Allowance.
U.S. Appl. No. 12/684,542, Jan. 30, 2012, Office Action.
U.S. Appl. No. 12/941,809, Jan. 30, 2012, Office Action.
U.S. Appl. No. 12/966,923, Feb. 3, 2012, Notice of Allowance.
U.S. Appl. No. 13/488,233, Feb. 5, 2013, Notice of Allowance.
U.S. Appl. No. 10/667,144, Feb. 15, 2012, Issue Notification.
U.S. Appl. No. 12/135,858, Feb. 16, 2012, Office Action.
U.S. Appl. No. 12/608,769, Feb. 10, 2012, Office Action.
U.S. Appl. No. 12/684,400, Feb. 13, 2012, Office Action.
U.S. Appl. No. 12/684,562, Feb. 16, 2012, Office Action.
U.S. Appl. No. 12/724,304, Feb. 10, 2012, Office Action.
U.S. Appl. No. 12/945,646, Feb. 21, 2012, Notice of Allowance.
U.S. Appl. No. 12/114,091, Apr. 5, 2012, Office Action.
U.S. Appl. No. 12/684,542, Apr. 16, 2012, Office Action.
U.S. Appl. No. 12/143,020, May 30, 2012, Issue Notification.
U.S. Appl. No. 12/393,877, May 21, 2012, Office Action.
U.S. Appl. No. 12/941,809, Jun. 1, 2012, Office Action.
U.S. Appl. No. 12/945,646, May 30, 2012, Issue Notification.
U.S. Appl. No. 12/973,204, May 30, 2012, Issue Notification.
U.S. Appl. No. 12/338,977, Jan. 19, 2012, Office Action.
U.S. Appl. No. 12/684,569, Jan. 27, 2012, Office Action.
U.S. Appl. No. 12/113,851, Mar. 29, 2012, Office Action.
U.S. Appl. No. 12/403,277, Apr. 3, 2012, Office Action.
U.S. Appl. No. 13/308,227, filed Nov. 30, 2011, Yibarren.
U.S. Appl. No. 12/688,065, Apr. 26, 2012, Office Action.
U.S. Appl. No. 13/028,041, filed Feb. 15, 2011, Von Oepen.
U.S. Appl. No. 13/030,922, filed Feb. 18, 2011, Cummins.
U.S. Appl. No. 13/039,087, filed Mar. 2, 2011, Palermo et al.
U.S. Appl. No. 13/112,618, filed May 20, 2011, Gianotti et al.
U.S. Appl. No. 13/112,631, filed May 20, 2011, Voss.
U.S. Appl. No. 10/682,459, Apr. 1, 2011, Notice of Allowance.
U.S. Appl. No. 11/396,731, Mar. 22, 2011, Office Action.
U.S. Appl. No. 11/427,297, Mar. 21, 2011, Office Action.
U.S. Appl. No. 11/958,281, Mar. 10, 2011, Office Action.
U.S. Appl. No. 12/113,851, Apr. 27, 2011, Office Action.
U.S. Appl. No. 12/114,031, May 11, 2011, Office Action.
U.S. Appl. No. 12/122,603, Mar. 3, 2011, Office Action.
U.S. Appl. No. 12/122,603, Apr. 22, 2011, Office Action.
U.S. Appl. No. 12/143,020, May 11, 2011, Restriction Requirement.
U.S. Appl. No. 12/403,277, Mar. 31, 2011, Office Action.
U.S. Appl. No. 12/481,377, Apr. 28, 2011, Restriction Requirement.
U.S. Appl. No. 12/955,859, May 26, 2011, Restriction Requirement.
U.S. Appl. No. 10/667,144, Oct. 28, 2011, Notice of Allowance.
U.S. Appl. No. 12/945,646, Oct. 26, 2011, Office Action.
U.S. Appl. No. 11/427,297, Oct. 31, 2012, Issue Notification.
U.S. Appl. No. 12/114,091, Nov. 8, 2012, Office Action.
U.S. Appl. No. 12/403,277, Nov. 5, 2012, Office Action.
U.S. Appl. No. 12/608,769, Nov. 5, 2012, Notice of Allowance.
U.S. Appl. No. 12/684,400, Oct. 16, 2012, Office Action.
U.S. Appl. No. 12/848,642, Nov. 9, 2012, Office Action.
U.S. Appl. No. 12/850,242, Oct. 17, 2012, Office Action.
U.S. Appl. No. 13/039,087, Nov. 6, 2012, Notice of Allowance.
U.S. Appl. No. 12/393,877, Dec. 13, 2011, Office Action.
U.S. Appl. No. 12/941,809, Dec. 13, 2011, Restriction Requirement.
U.S. Appl. No. 12/338,977, Nov. 28, 2012, Office Action.
U.S. Appl. No. 12/961,331, Dec. 4, 2012, Office Action.
U.S. Appl. No. 13/030,922, Dec. 18, 2012, Office Action.
U.S. Appl. No. 12/955,859, Dec. 15, 2011. Office Action.
U.S. Appl. No. 12/481,377, Jan. 3, 2012, Office Action.
U.S. Appl. No. 12/548,274, Dec. 28, 2011, Office Action.
U.S. Appl. No. 12/684,562, Dec. 28, 2011, Office Action.
U.S. Appl. No. 12/143,020, Feb. 23, 2012, Notice of Allowance.
U.S. Appl. No. 12/548,274, Mar. 2, 2012, Office Action.
U.S. Appl. No. 12/642,319, Feb. 27, 2012, Office Action.
U.S. Appl. No. 12/402,398, Mar. 13, 2013, Notice of Allowance.
U.S. Appl. No. 13/028,041, Jan. 4, 2013, Office Action.
U.S. Appl. No. 13/028,041, Feb. 26, 2013, Office Action.
U.S. Appl. No. 12/114,031, Mar. 6, 2012, Office Action.
U.S. Appl. No. 12/684,470, Mar. 23, 2012, Office Action.
U.S. Appl. No. 12/688,065, Mar. 13, 2012, Office Action.
U.S. Appl. No. 12/897,358, Mar. 5, 2012, Notice of Allowance.
U.S. Appl. No. 12/973,204, Mar. 7, 2012, Notice of Allowance.
U.S. Appl. No. 12/987,792, Mar. 13, 2012, Office Action.
U.S. Appl. No. 13/112,618, Mar. 29, 2013, Office Action.
U.S. Appl. No. 13/112,631, Mar. 29, 2013, Office Action.
U.S. Appl. No. 13/308,227, Apr. 10, 2013, Office Action.
U.S. Appl. No. 13/525,839, Apr. 1, 2013, Office Action.
U.S. Appl. No. 13/791,829, filed Mar. 8, 2013, Roorda et al.
U.S. Appl. No. 13/791,846, filed Mar. 8, 2013, Palermo.
U.S. Appl. No. 11/390,586, May 3, 2012, Notice of Allowance.
U.S. Appl. No. 12/684,400, May 9, 2012, Office Action.
U.S. Appl. No. 12/897,358, May 2, 2012, Issue Notification.
U.S. Appl. No. 12/966,923, May 16, 2012, Issue Notification.
U.S. Appl. No. 10/682,459, Aug. 10, 2011, Issue Notification.
U.S. Appl. No. 11/396,731, Sep. 1, 2011, Office Action.
U.S. Appl. No. 12/608,773, Jun. 7, 2012, Office Action.
U.S. Appl. No. 13/026,989, Jun. 8, 2012, Office Action.
U.S. Appl. No. 12/481,377, Jun. 21, 2011, Office Action.
U.S. Appl. No. 13/525,839, filed Jun. 18, 2012, Carley et al.
U.S. Appl. No. 11/427,297, Jun. 26, 2012, Notice of Allowance.
U.S. Appl. No. 11/767,818, Jul. 4, 2012, Issue Notification.
U.S. Appl. No. 12/338,977, Jul. 11, 2012, Office Action.
U.S. Appl. No. 11/390,586, Jul. 18, 2012, Issue Notification.
U.S. Appl. No. 12/608,773, Jul. 20, 2012, Office Action.
U.S. Appl. No. 12/684,569, Jul. 30, 2012, Office Action.
U.S. Appl. No. 13/039,087, Jul. 17, 2012, Office Action.
U.S. Appl. No. 11/675,462, Aug. 3, 2011, Office Action.
U.S. Appl. No. 12/114,031, Aug. 2, 2011, Office Action.
U.S. Appl. No. 11/675,462, Aug. 16, 2012, Issue Notification.
U.S. Appl. No. 11/744,089, Aug. 8, 2012, Office Action.
U.S. Appl. No. 12/481,377, Aug. 10, 2012, Notice of Allowance.
U.S. Appl. No. 12/850,242, Aug. 6, 2012, Office Action.
U.S. Appl. No. 12/955,859, Aug. 6, 2012, Office Action.
U.S. Appl. No. 12/608,769, Aug. 22, 2012, Office Action.
U.S. Appl. No. 12/642,319, Aug. 28, 2012, Office Action.
U.S. Appl. No. 12/684,562, Aug. 21, 2012, Office Action.
U.S. Appl. No. 13/222,899, filed Aug. 31, 2011, Carley et al.
U.S. Appl. No. 12/143,020, Aug. 31, 2011, Office Action.
U.S. Appl. No. 12/897,358, Aug. 22, 2011, Office Action.
U.S. Appl. No. 12/548,274, Sep. 10, 2012, Office Action.
U.S. Appl. No. 12/684,470, Aug. 30, 2012, Office Action.
U.S. Appl. No. 12/684,542, Sep. 13, 2012, Office Action.
U.S. Appl. No. 12/122,603, Sep. 23, 2011, Office Action.
U.S. Appl. No. 12/393,877, Sep. 29, 2011, Office Action.
U.S. Appl. No. 12/402,398, Sep. 20, 2012, Office Action.
U.S. Appl. No. 12/688,065, Oct. 12, 2012, Office Action.
U.S. Appl. No. 12/848,642, Sep. 20, 2012, Office Action.
U.S. Appl. No. 12/987,792, Sep. 17, 2012, Office Action.
U.S. Appl. No. 12/684,470, Dec. 20, 2011, Restriction Requirement.
U.S. Appl. No. 12/684,569, Dec. 20, 2011, Restriction Requirement.
U.S. Appl. No. 11/675,462, Dec. 22, 2011, Notice of Allowance.
U.S. Appl. No. 12/135,858, Jul. 13, 2011, Office Action.
U.S. Appl. No. 12/955,859, Jul. 21, 2011, Office Action.
U.S. Appl. No. 13/026,989, Sep. 16, 2011, Office Action.
U.S. Appl. No. 12/608,773, Jan. 7, 2013, Office Action.
U.S. Appl. No. 13/490,143, Jan. 4, 2013, Office Action.
U.S. Appl. No. 12/897,358, Jan. 12, 2012, Notice of Allowance.
U.S. Appl. No. 11/744,089, Aug. 8, 2013, Notice of Allowance.
U.S. Appl. No. 12/850,242, Aug. 6, 2013, Notice of Allowance.
U.S. Appl. No. 12/955,859, Aug. 1, 2013, Notice of Allowance.
U.S. Appl. No. 13/615,547, Aug. 7, 2013, Issue Notification.
U.S. Appl. No. 13/026,989, Aug. 23, 2013, Office Action.
U.S. Appl. No. 13/308,227, Sep. 11, 2013, Office Action.
U.S. Appl. No. 14/017,039, filed Sep. 3, 2013, Ellingwood et al.
U.S. Appl. No. 14/023,428, filed Sep. 10, 2013, Ellingwood.
U.S. Appl. No. 13/898,202, filed May 20, 2013, Walberg et al.
U.S. Appl. No. 10/786,444, Jul. 11, 2013, Notice of Allowance.
U.S. Appl. No. 10/908,721, Jul. 18, 2013, Notice of Allowance.
U.S. Appl. No. 11/396,141, Apr. 30, 2013, Office Action.
U.S. Appl. No. 11/427,309, Jun. 7, 2013, Notice of Allowance.
U.S. Appl. No. 11/532,325, Jul. 17, 2013, Office Action.
U.S. Appl. No. 11/744,089, Apr. 15, 2013, Office Action.
U.S. Appl. No. 12/106,928, Jun. 28, 2013, Office Action.
U.S. Appl. No. 12/106,937, Jun. 28, 2013, Office Action.
U.S. Appl. No. 12/338,977, Jun. 19, 2013, Office Action.
U.S. Appl. No. 12/848,642, Apr. 26, 2013, Office Action.
U.S. Appl. No. 12/850,242, Apr. 18, 2013, Office Action.
U.S. Appl. No. 12/941,809, Jul. 3, 2013, Office Action.
U.S. Appl. No. 12/955,859, May 16, 2013, Office Action.
U.S. Appl. No. 12/961,331, Jul. 3, 2013, Office Action.
U.S. Appl. No. 13/030,922, Jul. 18, 2013, Office Action.
U.S. Appl. No. 13/052,634, Feb. 8, 2013, Office Action.
U.S. Appl. No. 13/052,634, Apr. 22, 2013, Office Action.
U.S. Appl. No. 13/112,618, Jun. 7, 2013, Office Action.
U.S. Appl. No. 13/112,631, Jun. 26, 2013, Office Action.
U.S. Appl. No. 13/153,594, May 29, 2013, Office Action.
U.S. Appl. No. 13/490,143, Apr. 29, 2013, Notice of Allowance.
U.S. Appl. No. 13/525,839, Jul. 15, 2013, Notice of Allowance.
U.S. Appl. No. 13/615,547, Apr. 12, 2013, Notice of Allowance.
U.S. Appl. No. 13/615,547, Jul. 10, 2013, Issue Notification.
U.S. Appl. No. 13/791,829, May 29, 2013, Office Action.
U.S. Appl. No. 12/114,091, Jul. 7, 2011, Office Action.
U.S. Appl. No. 12/945,646, Jul. 6, 2011, Office Action.
U.S. Appl. No. 13/017,636, filed Jan. 31, 2011, Carley et al.
U.S. Appl. No. 13/026,989, filed Feb. 14, 2011, Cummins.
U.S. Appl. No. 10/264,306, filed Feb. 16, 2011, Issue Notification.
U.S. Appl. No. 11/767,818, filed Feb. 16, 2011, Office Action.
U.S. Appl. No. 11/396,141, Aug. 21, 2013, Office Action.
U.S. Appl. No. 13/028,041, Aug. 21, 2013, Notice of Allowance.
U.S. Appl. No. 13/490,143, Aug. 21, 2013, Issue Notification.
U.S. Appl. No. 10/908,721, Nov. 6, 2013, Issue Notification.
U.S. Appl. No. 11/396,141, Nov. 4, 2013, Notice of Allowance.
U.S. Appl. No. 11/411,925, Oct. 1, 2013, Office Action.
U.S. Appl. No. 11/744,089, Nov. 20, 2013, Issue Notification.
U.S. Appl. No. 12/122,603, Nov. 20, 2013, Office Action.
U.S. Appl. No. 12/688,065, Oct. 18, 2013, Office Action.
U.S. Appl. No. 12/850,242, Nov. 20, 2013, Issue Notification.
U.S. Appl. No. 12/941,809, Nov. 8, 2013, Office Action.
U.S. Appl. No. 12/955,859, Nov. 13, 2013, Issue Notification.
U.S. Appl. No. 12/961,331, Sep. 20, 2013, Advisory Action.
U.S. Appl. No. 13/052,634, Nov. 8, 2013, Office Action.
U.S. Appl. No. 13/112,618, Nov. 20, 2013, Office Action.
U.S. Appl. No. 13/153,594, Oct. 16, 2013, Notice of Allowance.
U.S. Appl. No. 13/791,829, Oct. 8, 2013, Notice of Allowance.
U.S. Appl. No. 11/113,549, Mar. 14, 2014, Notice of Allowance.
U.S. Appl. No. 11/396,141, Mar. 19, 2014, Issue Notification.
U.S. Appl. No. 11/411,925, Feb. 5, 2014, Notice of Allowance.
U.S. Appl. No. 12/106,937, Jan. 22, 2014, Office Action.
U.S. Appl. No. 12/848,642, Feb. 3, 2014, Notice of Allowance.
U.S. Appl. No. 12/941,809, Feb. 3, 2014, Notice of Allowance.
U.S. Appl. No. 12/987,792, Jan. 21, 2014, Office Action.
U.S. Appl. No. 13/030,922, Jan. 8, 2014, Notice of Allowance.
U.S. Appl. No. 13/222,899, Jan. 10, 2014, Office Action.
U.S. Appl. No. 13/898,202 Jan. 3, 2014, Office Action.
Related Publications (1)
Number Date Country
20080065152 A1 Mar 2008 US
Provisional Applications (1)
Number Date Country
60843325 Sep 2006 US